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Abstract
	Stress introduces a number of neurological and neurohormonal changes in
response to a number of stimuli, and can influence our relationship to rewarding
experiences. As such, it holds the potential of promoting vulnerability to addiction
to substances such as methamphetamine. While methamphetamine use and abuse
has been steadily declining, the fact remains that it and closely related drugs are
used in the treatment of conditions such as narcolepsy, weight loss, and attention
deficit disorder. In an effort to develop better patient assessment metrics in aiding
the physician in decisions of course of treatment, we ask the following questions:
Do chronic or acute stresses increase vulnerability to addiction? Does the age at
which stress is experienced contribute to risk? Using a restraint paradigm for stress
in a rodent model we answer this question through behavioral self-administration of
methamphetamine and attempt to deconstruct neurological mechanisms that may
account for stress-attributable differences in responding to drug. The answer: Yes,
chronic predictable emotional stress does increase methamphetamine escalation if
the stress is experienced during adulthood, but adolescent stress does not result in
either vulnerability to nor protection from addiction.
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Preface
	The late 1990’s and early first decade of the 2000’s saw the height of use and abuse
of the psychoactive drug methamphetamine (METH) or the closely related compound,
3.4-methylenedioxymethamphetamine (MDMA) (ONDCP, 2004). A portion of that surge in usage
was attributed to the ease with which METH could be synthesized from precursors like ephedrine or
pseudoephedrine found in over-the-counter sinus and cold medications. This made manufacture
of high-purity (~90%) METH inexpensive and enabled the establishment of not only large-scale
manufacturers in the United States, Canada, and Mexico, but also provided a ripe breeding
ground for small-scale “homegrown” operations. Thus, with ample supply of drug on the market,
economic forces made METH affordable in addition to accessible and allowed this drug to gain
favor over other psychoactive drugs such as cocaine.
	Figures posted by the Office of National Drug Control Policy (ONDCP) at the peak of METH
use in 2005 list the monetary cost to society in crime, medical treatment, and lost productivity
as $108 billion (ONDCP, 2014). This figure fails to tally the intangible and arguably longer-term
damage resulting from METH abuse (e.g., child neglect, depression and suicide, emotional and
physical damage from engaging in risky or impulsive behaviors). In the United States, policies were
enacted that restricted sales of pseudoephedrine and elevated vigilance within law enforcement
agencies, resulting in the decline of METH reporting (metrics of reporting include drug-related
emergency room visits, quantity of drugs seized, purity of drugs seized). However, it is important
to point out that while METH reporting has declined over the past decade, most recent available
data still cites monetary costs incurred in 2011 as $23.4 billion dollars, and balancing the decreases
seen in METH use are increases in the use of other illicit substances like heroin or off-prescription
use of oxycodone (US DEA, 2011).
It should also be noted that while widely known to the public as an illicit drug, METH
derivatives and closely-related chemicals are also prescribed by doctors to treat disorders of
narcolepsy, severe obesity, and, most commonly, attention deficit hyperactivity disorder (ADHD).
According to 2010 data provided by the Centers for Disease Control and Prevention (CDC) and
1

the National Institutes of Health (NIH), among children and adolescents ages 4-17, roughly 9.5%
were diagnosed with ADHD, and approximately half of those diagnosed were prescribed stimulant
medication to treat the disorder. In one study, as many as 35% of college students surveyed
reported abusing or misusing ADHD stimulant medication (Wilens et al, 2008). Prescription labels
for amphetamine-derived drugs like Adderall and Vyvance list the possibility of forming dependence
upon the drug, and the finding that the formation of drug tolerance requires dosage escalation
(not dissimilar to hallmarks of drug addiction), has also been acknowledged by the pharmaceutical
companies. Furthermore, accompanying these drugs are dosing instructions to prescribing
physicians that recommend increasing the dosage until the desired effect is achieved. These
observations are particularly worrisome given several studies in animal models that demonstrate a
number of molecular changes in the brain’s reward system among animals administered escalating
doses that are not observed in animals receiving static “binge” doses of METH (Chauhan et al,
2014; Kosheleff et al, 2012; Groman et al, 2012). Given the potential for methamphetamine and
amphetamine derivative medications to act as gateway drugs for addiction, it is necessary to shape
a rubric for patient risk assessment.
While biomarkers for addiction proclivity are still under investigation, patient histories
taken through standard medical office practice can gather information identifying pre-existing
physiological and psychological conditions, thus providing doctors with a potential metric for risk
assessment if correlations are known. For example, certain early life stressors such as childhood
sexual abuse and childhood neglect have been linked to drug and alcohol abuse (Dube et al, 2003;
Boyd, 1993; Marco et al, 2007), but a causal or mechanistic link between stress and addiction
remains to be identified. By self-report, chronic emotional stressors would appear to be a common
experience in modern society, but what level of severity or consistency is required to evoke such
responses toward drug? Furthermore, are these stressors more significant if experienced during
key developmental stages such as adolescence? With the established role of stress as an integral
component of relapse in recovering addicts (or as a means of re-instating extinguished drug seeking
behaviors in animal models), the type and perceived severity of patient stress experienced prior
2

to drug exposure may emerge as a risk factor for drug addiction (Bahi and Dreyer, 2014; Williems
et al; 2014; Graf et al, 2013; Morita et al, 2013; Brecht et al, 2012; Buffalari et al, 2012; Cruz et al,
2012; Preston and Epstein, 2011; Buffalari and See, 2009; Funk et al, 2006; Wang et al, 2007; Wang
et al, 2005; Shepard et al, 2004).
	To begin addressing these concerns, the present study employs a rat model of a strong
emotional stress (restraint) administered during mid-adolescence (PND 36-38) or during adulthood
(PND 60-64) under both chronic (daily for 14 days) and acute (single stress event) conditions.
Responses to methamphetamine are measured in these animals over 21 days of 6-hour intravenous
self-administration (IVSA) sessions to assess initial intake, overall intake, initiation of escalation,
and drug response patterns during the access periods.

3

1. Introduction
1.1 Structures and Signals of Stress Influence Reward
	Neurological mechanisms of reward and addiction are a tangle of interconnected and
co-regulated systems that incorporate functions of memory, emotion, metabolism, motor
planning, and executive processing. Of the legion of reward-associated and reward-modulatory
neurotransmitters, including dopamine, norepinephrine, epinephrine, 2-arachidonoylglycerol,
γ-aminobutyric acid (GABA), glutamate, serotonin, the endorphins, the enkephalins, and dynorphin,
dopamine (DA) is classically viewed as preeminent in motivational aspects of behavior to which we
simplistically ascribe the concept of reward.
	From a neuroanatomical perspective, the classic reward system is the dopaminergic
mesolimbic pathway (Figure 1.1). The key structures of this pathway are: 1) the ventral tegmental
area (VTA) which acts as a central integration station for myriad systems of the brain and initiates
dopaminergic signals; 2) the nucleus accumbens (NAcc) which contains dopaminergic terminals
from the VTA and is essential in experiencing rewarding effects of drugs or natural behaviors
(palatable foods, sex, nurturing, etc.), in distinguishing pleasurable from aversive stimuli, in motor
planning and physical response to stimuli, and in processing environmental cues; and 3) the

PFC

VTA
Dopamine-Mediated
Reward

NAcc
Figure 1.1 Streamlined View of Key Mesolimbic Structures
Highlighted here are the two classic structures of mesolimbic reward pathway. The ventral tegmental area initiates dopaminergic signaling to the nucleus accumbens but also receives GABAergic projections from the nucleus
accumbens essential to regulating dopaminergic signaling (Ikemoto et al 1997). Though not a part of the mesolimbic pathway proper, the PFC is illustrated due to its participation in pathway modulation.
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prefrontal cortex (PFC) which imposes cognitive influence upon actions and drives and is often
referred to as the seat of self-control (Goto and Grace, 2008; Faure et al, 2010; Fuchs et al, 2004;
Fuchs et al, 2008, Lemos et al, 2012).
	As the nucleus of motivation and aversion, the NAcc makes use of information stemming
from stress responses to discriminate between feeling a thrill of fear while watching a scary movie
and feeling dread or terror when actually walking alone in a dark alley. Direct neural connections
from the amygdala (AMYG) give emotional context; from hippocampal projections, declarative
memory exerts influence; from PFC projections impulsive actions are moderated. Together, this
connectivity lends perspective to the associative environmental cues that are processed in the
NAcc. Even indirectly connected brain structures like the paraventricular hypothalamic nucleus
(PVH) can exert influence through intervening brain regions and remote glands in the body such as
the adrenal cortex can send signals through circulation. An understanding of the mechanisms that
underlie normal functioning of the stress and reward systems is needed in order to describe some
of the points at which these systems intersect. On that foundation, we can then overlay the actions
of METH. Finally, to this we can add aspects of key developmental differences in both stress and
reward responses exhibited during the period of adolescence that may suffer dysregulation and
alter future behavior toward addictive substances. Let us begin with stress as our cornerstone.
1.1.1 Stress Defined as Distress
	First, stress is defined in its simplest terms as any challenge to a system’s homeostatic
balance. However, stressors may either elicit a state of eustress (beneficial challenge) such as going
out for a pleasant jog, or distress which constitutes a threat to our well-being either emotionally
or physically (like preparing for a dissertation defense). Distress is what we typically think of when
using the term “stress” and this common definition will be applied here as well.
	The neurological outcomes of stress are determined through complex physical and emotional
processing that recruit distinct neuronal populations from defined brain regions predicated, in part,
by incoming information. Physical stress such as hemorrhage carries information from baroreceptors
to the nucleus of the solitary tract prior to stimulating neurons in the hypothalamic seat of stress,
5

the PVH, without recruiting cortical structures. Pain, which represents a combined physical and
emotional stress, stimulates sensory nerves in the periphery which send information to a host of
cortical structures that enable interpretation of the stimulus, ascribe emotional texture, stimulate
physiological responses that attempt to ameliorate the pain, and generate motor responses in
addition to recruiting neurons in the hypothalamus. Emotional stress such as being confined to a
small space without the possibility of escape or being exposed to predator odor is perhaps a less
“messy” and more relatable stress. It, too, is characterized by a unique neuron-recruitment profile
that involves emotional processing, declarative and associative memory, motivation states, and
(sometimes) locomotor responses. Regardless of the stress, however, the core neuroendocrine
responses evoked under the differing conditions of stress and even eustress are shared.
1.1.2 Stress Activates the Sympatho-Adrenal-Medullary Axis and Generates Neurotransmitters
Epinephrine and Norepinephrine
	Stress first activates the sympatho-adrenal-medullary or SAM axis (this is also the cascade
known as the “fight or flight” response). The SAM axis prepares the body for immediate response
to a stressor, using input from the sympathetic nervous system to release epinephrine (Epi) and
norepinephrine (NE) from nerve terminals and the medulla of the adrenal glands (Ulrich-Lai and
Herman, 2009; Johnson et al, 1992) (Figure 1.2). These neuroendocrine mediators stimulate
vasoconstriction in the viscera and increase blood resources to heart and skeletal muscle, vasodilate
the bronchioles for increased blood oxygenation, and increase heart rate.
Concurrent with peripheral secretion of Epi and NE, in the brain there is secretion of NE by
neurons in the locus coeruleus (LC). This structure is a nexus of connectivity that receives projections
from medial prefrontal cortex (mPFC), lateral hypothalamus (LH), and sends projections to neurons
in the amygdala (AMYG) and extended AMYG (including bed nucleus of the stria terminalis or
BNST), thalamus , hypothalamus and ventral tegmental area (VTA) (Valentino et al, 1992; Radley
et al, 2008; Kravets et al, 2015; Wallace et al, 1989; Lopez et al, 1999; Buffalari and Grace, 2009;
Pacack et al; 1995). Together, NE released from SAM activation and from the LC stimulates the
second branch of the stress response, the hypothalamic-pituitary-adrenal (HPA) axis.
6

1.1.3 The HPA Axis Is the Second Branch of Stress Response and Produces Three Major Products
Whereas adrenaline can be viewed as the neuroendocrine end product in SAM axis
activation, the end product for the HPA axis is cortisol in humans or corticosterone in rats
(collectively referred to here as CORT). The HPA axis starts with the secretion of corticotropinreleasing factor (CRF) from distinct subpopulations of neurons in the PVH depending on the nature
of the stress applied. CRF then enters the hypophyseal portal system which carries the signal to
the anterior pituitary and stimulates release of adrenocorticotropic hormone (ACTH) (Kawata et
al, 1983; Ulrich-Lai and Herman, 2009; Smith and Vale, 2006). Finally, the adrenal cortex, under
the influence of ACTH produces CORT which serves to not only influence emotional processing,
memory formation, and immune and metabolic functions, but also to negatively regulate the HPA
axis at the level of CRF and ACTH production (Figure 1.2) (Ulrich-Lai and Herman, 2009; Smith and
Vale, 2006). Negative feedback for the HPA axis occurs at several levels. CRF can actually inhibit the
production of additional CRF. ACTH inhibits ACTH and CRF production, and CORT acts to suppress
further secretion of additional CORT, ACTH and CRF. Furthermore, CORT has two mechanisms of
negative feedback: fast and slow. Fast feedback is a non-genomic mechanism that shows assayable
effect within 10 minutes of stress stimulus. Slow feedback requires 30 minutes after stress onset
(Maser-Gluth et al, 1984; Popoli et al, 2012). In short, while the focus of SAM pathway activation is
immediate survival, HPA axis activation serves to support recovery and homeostatic return through
subsequent immune and metabolic adjustments. Both branches of the stress response are also
vital in memory and learning, and both systems are subject to dysregulation be it from repeated or
prolonged activation of the stress response or from inappropriate processing of the conditions and
qualia of the presented stress or memory of the stress.
1.1.4 Anatomical Connections between PVH and NAcc Are not Direct
	Examining direct neuronal projections among structures provides an anatomical perspective
of the general flow of information in the stress response as it relates to reward. Looking at the lines
of structural connectivity (Figure 1.3), we find that direct links between the “stress nucleus” (PVH),
7

Sympathetic Adrenal Medulary

Sympathetic
Nerves

Stress

Hypothalamic Pituitary Adrenal

Locus
Coeruleus

Paraventricular
Hypothalamic
Nucleus

NE

CRF

Anterior
Pituitary

ACTH

Adrenal
Medula

Epi

Adrenal
Cortex

NE

CORT

Figure 1.2 SAM Pathway and the HPA Axis in Parallel
Experience of a stressor initiates a cascade of events to allow immediate response and enable recovery. Arrows
indicate activation increased production of signal. Note that while CRF induces NE secretion in the LC, NE serves
to negatively regulate the system. CORT provides negative feedback to the HPA axis. Flat lines indicate suppression. Signaling molecules are rendered in hexagons.

and the “reward/motivation” nucleus (NAcc) have yet to be documented in the literature. However,
within the mesolimbic system, the VTA does receive CRF projections from the PVH providing a
second-degree relationship between PVH and NAcc in addition to a first-pass in modulating final
DAergic release in the NAcc and PFC (Wang et al, 2005; Swanson et al, 1983; Roderos et al, 2007).
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There are numerous additional structures that pass information to and from the PVH and the NAcc
based on several experiential aspects, including: emotion (AMYG), executive function (PFC), and
feeding or metabolic status (LH) (Figure 1.3).
	CRF receptors (CRFRs) are also distributed throughout the brain including in the NAcc,
indicating that these cells are capable of being activated by CRF secreted from the PVH. One
caveat is that CRF is not solely secreted by cells in the PVH under conditions of stress. Several other

Emotion

Stress

Feeding

PVH

LC

AMYG

LH

Executive Function
PFC

VTA

Reward
NAcc

Pain Processing, Attention, Active Memory

MDM

VP

Figure 1.3 Structural Connectivity of Stress and Reward
This illustration is non-comprehensive in connectivity among the myriad structures linking the stress and reward
pathways of the brain. Hippocampal connections have been omitted. The nigrostriatal pathway is not addressed in
this image. Mediodorsal thalamic nucleus (MDM) and lateral hypothalamus (LH) are not addressed in this text but
are included given the role MDM plays in experiential attention and that LH contributes in appetitive drives, both
of which are emerging as an increasingly significant factors in the broader addiction story. Structure afferents and
efferents were obtained through use of BAMS (Bota et al, 2003; http:\\brancusi.usc.edu).
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structures that are in communication with the NAcc (AMYG, BNST, and hippocampus) have also
been shown to produce CRF mRNA (Palkovits, 2000; Givalois et al, 2000; Funk et al, 2006). Thus it is
difficult to definitively draw direct links between stress and reward structures without conducting
challenging assays to directly assign the source of CRF acting in the NAcc as one specific structure.
It is, however, possible to at least demonstrate that the PVH and NAcc are similarly activated under
conditions of a specified stress paradigm, denoting the potential contribution of PVH-sourced CRF
(please see the Results section for further review of neuronal recruitment in these structures in
response to our stress paradigm).

1.2 Examining Molecular Mechanisms Involved in Motivation and Stress
Placing molecular events into anatomical context: DA neurons in the VTA release DA in the
NAcc following an action potential. However, it is good to be acquainted with the multiple specific
processes involved in DAergic neurotransmission (or at least the highlights thereof) in order to fully
appreciate the manner in which stress can impact the functioning of the system. The main stages
of the DAergic cycle are: DA synthesis, vesicular packaging, vesicular release, receptor binding, and
DA clearance (Figure 1.4). Synthesis of DA involves conversion of tyrosine into L-DOPA by tyrosine
hydroxylase (TH) (for review, see Daubner et al, 2011). This enzyme is particularly significant as it
is the rate-limiting enzyme in the conversion process. Expression of TH is governed in part by the
dopamine autoreceptor D2 (Best et al, 2009; Daubner et al, 2011; Ford, 2014). After synthesis, DA
(in addition to other monoamine neurotransmitters) is taken into vesicles via vesicular monoamine
transporter 2 (VMAT2) and retained until action potentials spur vesicular binding and release of
DA into the synaptic cleft. Released DA then can either bind to post-synaptic DA receptors (D1
being the best characterized of these in addiction literature), bind pre-synaptic receptors (the D2
autoreceptor), be degraded in the synaptic cleft, or be taken back into the pre-synaptic neuron via
dopamine transporter (DAT) and metabolized. While reward is mediated through D1 and D1-type
receptors, the function of D2 on DA synthesis identifies this receptor in a critical regulatory role.
1.2.1 The Stress Hormone CORT Has Specific Means of Influencing DA Neurotransmission
	CORT has well-characterized receptor-mediated effects both pre- and post-synaptically.
10
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Figure 1.4 The Dopaminergic Cycle
Dopaminergic signaling is controlled, in part, through negative feedback mechanisms governed by D2 binding
DA. Additional mechanisms of clearance are intracellular and extracellular breakdown of the monoamine into
homovanillic acid (HVA) or 3,4-dihydroxyphenyl acetic acid (DOPAC) or 3-methoxytyramine (not shown). This is
mediated through activities of monoamine oxidases (MAOs) or chatecol-O-methyltransferase (COMT).

Pre-synaptically, CORT binds glucocorticoid receptor (GR) and enhances DA release via glutamate
release (Figure 1.6). Post-synaptically, reward-related effects occur through CORT/GR interactions
with transcription factors such as Fos to induce systemic changes. Reward related effects can
also occur through secondary signal cascades that promote Ca2+ uptake and alter the pH of
the environment with the net result of shifting arachidonic acid metabolism to produce the
endocannabinoid 2-arachidonoylglycerol (2-AG) (Hill, 2010) (for reviews see Popoli et al, 2013 and
Lopez et al 2008). Furthermore, in the NAcc, the presence of CORT may actually hamper DA
clearance through disrupting the function of organic cation transporter 3 (OCT3) (Graf et al, 2013).
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Taken together, CORT not only acts to facilitate stress coping and recovery and inhibit the HPA
axis, but also contributes to reward circuitry function by facilitating neuronal excitation, promoting
production of endocannabinoids, and enhancing DAergic signaling in the synaptic cleft.
1.2.2 The Influence of CRF on Addictive Behaviors Is Based on Receptor, Location and Ligand
	CRF and signaling events mediated through CRFRs also play a large role in stress-associated
and cue-related drug-seeking behaviors (Figures 1.5 and 1.6). Administration of CRF to multiple
locations in the brain including NAcc, AMYG, VTA, or BNST have been shown to facilitate drug
reinstatement for cocaine, methamphetamine, heroin, or alcohol. Furthermore, blockade of CRFRs
have been shown to attenuate stress-induced drug reinstatement (Lu et al, 2001; Lu et al 2000; Le
et al, 2000; Shaham et al, 1997; Erb et al, 2001; Erb et al, 1999). However, the receptors governing
attenuation of reinstatement appear to differ based on the region of the brain examined. For
example, blockade of CRFR1 in the BNST is effective in diminishing reinstatement of drug-seeking,
whereas in the VTA this is achieved only by blocking CRFR2 and not CRFR1 (Erb et al, 2001; Meloni
et al, 2006; Wang et al 2006; Wang et al 2007; Lu et al, 2001; Lu et al 2000; Shaham et al, 1998;
Williams et al, 2014).
	To further complicate matters, the urocortins (UCNs) are additional CRFR ligands that, like
CRF, are upregulated by stress. CRFRs and their ligands are differentially expressed throughout the
brain, and exhibit variable affinities. CRFR1 is relatively ubiquitous, binds UCN1 and has a higher
affinity for CRF than does CRFR2 (Hauger et al, 2009). CRFR2 is far more specific in localization,
having been documented in NAcc, BNST, AMYG, LS, and the dorsal raphe nucleus (Lemos et al,
2012; Van Pett et al, 2000; Chalmers et al, 1995), and displays higher affinity for UCN2,3 but will
also bind UCN1 and CRF. Furthermore, the activation of these receptors appears to govern different
functions in the stress response.
In CRFR1 knockout mice, anxiety measures associated with alcohol withdrawal are
significantly reduced (Timpl et al, 1998). Coupled with the observation of decreased ACTH
production in these same mice, binding of CRFR1 can be considered anxiogenic. Conversely, CRFR2
knockouts present a more rapid elevation in ACTH and CORT levels post-restraint stress and a marked
12
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Figure 1.5 Stress-evoked Non-CORT Molecular Cascades
Urocortins (UCN) and CRF both trigger a cascade of events throughout sites in the brain and body. CRFR2 in
the NAcc and HTH has higher affinity for UCN2 and UCN3 than for CRF (Hauger et al, 2009). These UCNs are
also stress-inducible and are specifically distributed among multiple structures that contribute to connections
between reward and stress. Arcuate nucleus (ARC), brain stem (BS), hypothalamus (HTH) lateral septum (LS).
Downstream products such as cFos are particularly relevant in the context of neuron activation assays where it
acts as a classic and well-characterized marker in immunohistochemistry. FosB (and ΔFosB) overexpression has
been demonstrated to promote reward-seeking or addictive behaviors (Nestler, 2011). BDNF overexpression,
particularly in VTA, can induce a shift in GABA-ergic signaling from inhibitory to excitatory and induce addictive
behaviors (Vargas-Perez et al, 2009).

difference in behavioral measures of anxiety in the elevated plus maze, suggesting that CRFR2 has
an anxiolytic function (Bale et al, 2000). As an aside, Neufeld-Cohen et al (2010) published a study
demonstrating that the UCNs as a whole are essential in appropriately moderating anxiety after
stressors have passed, and may represent yet another point of vulnerability in the dysregulation of
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stress processing which may contribute to inappropriate responses to rewarding stimuli. To further
illustrate the complexity of the relationship of the CRF system to reward, the CRFR2 agonist UCN3
administered in the central amygdala (CeA) of ethanol-dependent rats was shown to decrease
ethanol self-administration, but paradoxically increases self-administration in non-dependent rats
(Funk and Koob, 2007).
Iemolo et al (2013), in a complex examination of regular versus palatable food diets,
administered a selective inhibitor of CRFR1 in three regions of the amygdalar complex. When
administered the CeA, palatable food consumption was enhanced, and anxiety behaviors were
mitigated in animals experiencing subsequent palatable food withdrawal. Infusions into the
basolateral amygdala increased normal food intake but abolished palatable food withdrawal
hypophagia in a dose-dependent fashion and failed to diminish withdrawal-induced anxiety. No
differences were observed for animals administered antagonist in the BNST. Collectively, dose/
strength of signal and location in the brain can profoundly alter the cross-influence and expression
of stress-related and motivation-related behaviors.
	Finally, in mice, Lemos and colleagues (2012) documented conditioned place preference
(CPP) for the chamber associated with CRF infusions into the NAcc, suggesting that this provided a
pleasant or rewarding stimulus. Furthermore, CRF increased DA release through the activation of
both CRFR1,2. However, when mice were severely stressed through a forced swim paradigm, CRF
no longer elicited DA release, and mice avoided the CRF-associated chamber in CPP, suggesting
that CRF administration was now perceived as an aversive stimulus. These effects were persistent
among animals tested even 90 days after forced swim, demonstrating that at least certain stressful
events may induce long-term alterations in reward perception.
1.2.3 Assembly of a Unified Picture of Stress at the DA Synapse
	Figure 1.6 encapsulates the events of stress and subsequent effects on DA neurotransmission.
In summary, CORT and CRF, through GR and CRFR1, respectively, facilitate DA release through
alterations in CA2+ influx and increase of glutamatergic activity. CRF (or UCNs) acting on CRFR2
increases GABAergic activity with a net result in decreasing DA release (Freund et al, 2003). Fast
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Figure 1.6 The Intersection of Stress and Dopaminergic Signaling
Contributions from both early and late products of the HPA axis have opposing functions that both enhance and
inhibit DA release. While CORT immediately functions to promote DA signaling, subsequent effects of CORT lead
to the suppression multiple pathways of neuron excitation by way of endocannabinoid signaling. Actions of CRF
largely depend upon the receptor that binds it with CRFR2 resulting in GABA inhibition and CRFR1 resulting in glutamate excitation. Highlighted in gray are the inhibitory pathways of DA release in the NAcc.

feedback mechanisms for CORT also engage a pathway ultimately reducing DA release. Fine-tuning
these responses involves a balance of the signals stemming from unique brain nuclei. In this
manner, stress and reward are intimately interconnected.
1.3 METH—Molecules, Metabolism, and Mechanisms
	The following section seeks to address the aspects in which METH interacts with the
dopaminergic system and can introduce dysregulation resulting in escalation and addition. The
general overview is that METH’s properties as a highly lipophilic weak base enable the drug to
easily cross the blood brain barrier (BBB) and to passively cross membranes permitting rapid and
potent effects, and to collect in acidic vesicles thereby shifting the internal pH. Taken from another
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viewpoint, the lipophilicity allows access while basicity and molecular structure support METH’s
functional effects.
1.3.1 METH Structure and Properties Enable Multiple Interactions with Monoaminergic
Machinery
	The chemical characteristics of METH allow it to enter cells and vesicles through two modes:
1) high lipophilicity permits passive diffusion across membranes; 2) structural homology with
monoamines allows active or facilitated transport via membrane transporters. To gain perspective
on the structural similarities of amphetamine-class drugs and the monoamine neurotransmitters,
Figure 1.7 is provided.
	As a weak base, once METH is concentrated within monoamine vesicles through either
passive diffusion or active transport, vesicle pH rises, collapsing the gradient required for
monoamine accumulation. In addition to this, vesicular monoamine transporter 2 (VMAT2), is
reversed in function, and actively transports DA, serotonin (SER) and NE into the cytosol of the
neuron terminals (Wimalasena, 2011). This surge in the cytosolic concentration of monoamines
contributes to a shift in the functioning of their reuptake transporters (DAT, SERT, and NET) from
a net intake of monoamine signal from the synaptic cleft to a net outflow of neurotransmitters
from the presynaptic terminal. Furthermore, there is evidence suggesting that METH and
other amphetamines may also physically interact with transporters (particularly with DAT), by
partially blocking monoamines from reaching active sites and by inducing a conformational shift
in transporters that results in the net export of monoamines (Sulzer et al, 2005). Among the
monoamines affected by METH exposure, the greatest effect is seen in DA release, making the
dopaminergic system one of particular interest in this field of research (Sulzer et al, 2005).
While structural homology among METH and other amphetamine derivatives does permit
physical interactions with transporters, it does not appear to directly interact with post-synaptic
monoamine receptors. Thus, it does not appear to act as a signaling analogue. It does, however,
indirectly influence the activation of receptors by way of increasing the concentration and duration
of monoaminergic signal in the synaptic cleft. In this manner, extended use of METH can alter the
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Figure 1.7 Structural Homologies Among METH, METH-Related Compounds and Monoamines
expression of monoamine receptors including the autoregulatory dopamine receptor D2.
	As it relates to METH addiction, in cases of high-dose consumption, TH is significantly
reduced in control samples from striatal tissues including the NAcc, an effect that has been
correlated with damage to dopaminergic neurons (Broening et al, 1997; Larsen et al, 2002; Bowyer
et al, 2006; Krasnova et al, 2010). However, in the initial stages of METH exposure, TH expression
transiently increases. This, coupled with the reversals seen in VMAT2, leads to DA increases in the
cytosol of the pre-synaptic neuron which not only provides substrate for DAT to transport into the
synaptic cleft, but also creates a condition of oxidative stress in the cell. Eventually, these oxidative
conditions are believed, in part, to contribute to formation of inactive DAT complexes seen during
the early stages (24 hours) of withdrawal (Hadlock et al, 2010; McFadden et al, 2012). The net
17

result of long-term drug exposure has been recorded as a downregulation of dopamine receptors
and a decrease in DAT that can lead to depressive affect due to dampened dopaminergic signaling
thus requiring ever-increasing amounts of drug to attain the same level of euphoria (Volkow et al,
2001; Krasnova et al, 2010; Schwendt et al, 2009; Koob and Le Moal, 1997 and 2008; Wilson, 1996;
Wang, 2012). To summarize a list of these effects, Figure 1.8 compares the normal versus METHinduced conditions at the dopaminergic terminals in the NAcc.
1.3.2 METH Metabolism Provides Insights into Withdrawal Symptom Appearance and
Abatement
	Though not pivotal to this study which focuses on pre-drug exposure conditions and
subsequent behavior toward freely-accessible drug, the time course of METH metabolism
should at least be mentioned, as it is relevant to protocols employed by this study in post-study
tissue collection and may inform analysis of drug acquisition behavior. With respect to routes
of administration, prescription METH and METH derivatives are taken orally and off-label use of
these compounds typically utilizes the oral route, though METH can also be inhaled (smoked) or
intravenously injected. The route of administration does influence the duration and concentration
of METH in the brain, though clearance mechanisms have been most extensively documented in
oral administration routes.
	Once internalized, METH enters the bloodstream and is distributed readily to highly bloodperfused sites including the heart and brain. The euphoric effects of METH are reported to last
for as long as four hours, and the plasma half-life is extensive (12 hours) relative to that of similar
sympathomemetics like cocaine (Chauhan et al, 2014; Cho et al, 2002). It should also be noted that
METH exposure activates the SAM and HPA axis thus providing stress influences that may enhance
the rewarding state. The dominant route of METH clearance occurs through urination, though the
efficiency with which this occurs depends largely on urine pH (Davis,et al, 1971). METH undergoes
several steps of conversion, including hydroxylation and demethylation, the latter of which
produces the psychoactive drug amphetamine (Figure 1.7) (Li et al, 2009). Complete clearance of
METH and metabolites occurs between 48 and 72 hours after ingestion (Caldwell et al, 1972). The
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Figure 1.8 Summarizing the Effects of METH on the Dopamine Cycle: This is your brain. This
is your brain on drugs.
The immediate effects of METH exposure are demonstrated below. TH is transiently upregulated and contributes
to a growing DA pool in the cytosol. The function of VMAT2 and DAT are reversed and DA is no longer vesicularized
leading to more cytosolic DA which now facilitates formation of reactive oxygen species (ROS). Oxidative stress
facilitates the formation of DAT complexes. Intracellular and extracellular MAO activity is hindered, allowing the
pool of DA to persist and bind DA receptors until the cells can no longer support this. Long-term abuse leads to
retraction of dopamine receptors and reduced DAT that can persist for many months (not illustrated) (Volkow et
al, 2001).

span of time between plasma half-life and full clearance also marks the peak period of withdrawal
symptoms (craving, anxiety, depression) in abstaining chronic METH users (McGregor et al, 2005).
In these withdrawal states, the emotional anxiety and drug craving experienced represents an
additional source of stress stimulus which has been implicated in driving drug-seeking behavior
and drug relapse (Koob et al, 2008; McGregor et al, 2005; Jang et al, 2013).
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1.4 Adolescence Represents a Period of Change in Stress and Reward Responses
	Armed with a basic understanding of the interplay of stress and reward systems and the
means by which METH and closely related compounds disrupt this function, we can now highlight
aspects of adolescent development that may suggest stress as an influential factor in later responses
to METH. Published research addressing changes in stress response systems and the mesolimbic
reward pathway during the adolescent period is a growing body of work, though still less prolific
than what is found concerning responses in adults and particularly adult males. However, an
excellent review by Burke and Miczek (2014) compiles much of that research and provides, quite
elegantly, a thorough treatment of this very topic. Here, I highlight some of the content provided
by those authors and offer observations found in additional resources.
	First, an effective chart published by Burk and Miczek succinctly illustrates the developmental
progression of the stress and dopamine reward systems from PND 10 through adulthood based
on literature review. Presented in Figure 1.9 is a modified version of their diagram, highlighting
the findings for nucleus accumbens and HPA markers and layering an additional observation. In
HPA axis function, the response of ACTH (an intermediate product of HPA axis activation) follows
an inverted “u” curve across the duration of adolescence whereas CORT levels gradually drop over
the course of early adolescence and stabilize mid-way through the period (Foilb et al, 2011). In
higher resolution, the time course work conducted by this group shows that early ACTH responses
to stress (30 minutes post-restraint stress onset) are more exaggerated from PND 30-50 whereas
circulating and adrenal CORT are sharply elevated at 30 minutes post stress initiation and maintain
elevated levels even 90 minutes after stress. This same effect is not seen in PND 40+ animals
whose CORT time course closely tracks that of adults (PND 60+).
	For dopaminergic activity in the NAcc, there are also distinctions in development, if
somewhat less dramatic than what occurs within PFC (data not illustrated). As depicted in our
version of the chart, during the early stages of adolescence there is an increase in what is termed
in the review as “dopaminergic fibers” found in the NAcc. This measure was originally obtained
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Figure 1.9 Phases of Stress and Reward Shifts Across the Early Life of the Rat.
Gray shaded region denotes the broadly-accepted age range for adolescence in rats. Grey lines establish DA-related baseline conditions across the developmental span. Black lines are stress-induced levels observed in stress-related hormones. Vertical axis represents an arbitrary unit of measure.
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in autoradiography studies of DAT which showed relatively low levels of DAT label at PND 7 that
increased by PND 60 by ~6-fold (Tarazi et al, 1998). Given that DAT activity increases steadily
within the NAcc suggests that DA clearance mechanisms are in development in the early stages
of adolescence with the potential effect of greater signal delivered upon motivating stimuli (an
outcome supported in human studies reported in Ernst et al, 2005 later discussed), and may rely
more heavily upon D2-mediated regulation or the limiting of TH available in NAcc terminals. This
last speculation is enhanced by examining the work of Naneix et al (2012), and Leslie et al (1991)
which contributed to the DA receptor track depicted in Figure 1.9. First, TH expression in the
NAcc of early adolescents is significantly lower than adults with a spike observed at PND 45 and
continued increase throughout development. The nadir of TH coincides with lower presence
of DAT and dopamine receptors (including autoreceptor D2), placing putative natural limits on
available DA during a time of impaired DA regulation. This is further supported by accompanying
observations of DA elevation at PND 45 when regulatory systems are coming online (Naneix et al,
2012). The initial increase in TH occurs not long after DAT stabilizes at adult levels. Furthermore,
while the receptors are not parsed out in the figure, distinctions in receptor presence are important
to note. D2 spikes in quantity at PND 35 (as do D5 and D4) perhaps in presage of increasing
demands for dopaminergic regulation in the NAcc in contrast to D1 receptors which appear early
in development (PND 7) and stabilize by PND 14 at only slightly elevated levels (Leslie et al, 1991)
(Naneix et al, 2012).
	To examine behavioral paradigms that suggest long-term (persisting into adulthood)
consequences stemming from stress exposures, the literature is difficult to correlate. A diversity
of stress paradigms are applied at various stages in adolescent development and can yield highly
variable results. However, focusing on studies that are compatible in age and at least semiconsistent in model, we can glean a few examples of stress and the impact on feeding, anxiety
(evidence of a dysregulated stress response), and response to rewarding stimuli (often sucrose).
In rat models using acute versus chronic restraint and immune challenge, acute and chronic
restraint administered during early adolescence had long-lasting behavioral and physiological
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effects when animals were subsequently stress-challenged as adults (Traslaviña et al, 2014). CORT
levels in adults exposed to an acute stressor were significantly higher than controls, an effect not
seen in immune-challenged animals. However, in behavioral measures, both chronic restraint and
chronic immune challenge resulted in decreased time spent in the open arms of an elevated plus
maze (EPM) test, indicating that both conditions experienced as an adolescent increased a measure
of anxiety among adult animals. Chronic restraint used in a comparison against chronic variable
stress and chronic isolation stress also produced immediate and long-term changes in body weight,
and decreased intake of a palatable substance, suggesting that restraint stress in particular was
effective in augmenting reward and motivation responses long-term (Bourke and Neigh, 2011).
Additionally, social isolation stress during adolescence was observed to decrease consumption of
palatable substances during the adolescent window in a study by Hong et al (2012). Body weight
discrepancies observed in chronically restrained adolescents was supported by work from Cruz et
al (2012) when compared to chronic variable stress and control animals in addition to decreased
locomotor responses in a novel environment.
In studies examining human responses in adolescents versus adults in a gambling paradigm,
Ernst and colleagues demonstrated that the nucleus accumbens of teenagers was more active in
response to reward withholding and showed less change in the amygdala versus adult counterparts
(Ernst et al, 2005). This demonstrates a certain amount of emotional resilience in response to
negative outcomes, and more robust motivated behavior despite the occurrence of failure among
adolescents. This demonstrates distinct differences in reward and emotion processing that may
also help refine the nature of adversity that spawns adverse addiction outcomes.
	Thus, as we look at the intersection of drug and reward maturation, the blanket assumption
is that any acute or chronic stress applied during periods of adolescent development will influence
later responses to stress and reward. The growing body of literature suggests that not only the type
of stress applied, but the duration and the age at which that stress is administered is an integral
determinant in future responses to addictive substances and rewarding stimuli. Of the systems
reviewed, restraint stress appears to offer consistent persistence of influences on measures of
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reward and anxiety and offers a system that is not only well characterized in adult animal models
but one that is a relatively “clean” emotional stress. Examining the developmental aspects of
stress and reward, PND 36-54 offers a unique window of relatively well developed DA signaling that
overlaps with transitions of stress feedback mechanisms from juvenile to near-adult levels, making
this an intriguing age to investigate.
1.5 Summary of the Literature Highlights a Need to Assess Stress as a Risk Factor of Addiction
•

Stress can produce variable outcomes on the functioning of reward circuitry including the
efficacy with which DA is released in the mesolimbic dopamine reward pathway.

•

Components of stress are associated with drug relapse in recovering addicts or extinguished
animals.

•

Variability seen in behavioral measures (including behavior toward drug) and in physiological
responses to stress is dictated by the type of stressor applied, the duration or repetition of
exposure, and the age at which it is applied.

•

Depending upon the paradigm, stress administered during adolescence can alter stress and
reward responses both behaviorally and molecularly well into adulthood, potentially as a
function of disruption in developmental events.

•

Restraint stress is a well-characterized paradigm that offers a strong emotional stress capable
of inducing persistent effects (including from adolescence to adulthood) without introducing
aspects of physical stress.

•

METH and related compounds can be prescribed during adolescence or adulthood for
treatment of certain conditions, necessitating a means by which patients at risk for addiction
can be identified during physician visits.

•

Key molecular components of the dopamine reward pathway can be affected by METH
exposure.

•

METH exposure and METH withdrawal activate the SAM and HPA axis but little is known about
the influence stress exposures prior to METH exposure exerts on behavior toward that drug.

	As stated in the Preface, the purpose of this body of research is to establish more defined
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measures of stress criteria required to establish METH addiction vulnerability with the goal of
contributing to patient assessment prior to prescribing METH-like medications. The aims of this
research, therefore, are to determine:
1) If chronic exposure to emotionally stressful events prior to drug exposure increases vulnerability
for drug use escalation; and
2) If ontogeny exerts influence over the impact of stress pre-exposure on drug abuse vulnerability.
Given the contributions of stress to the function of the reward system we hypothesize that chronic
stress will result in escalation regardless of the age of administration and that these changes will
be reflected in alterations to the expression of dopaminergic markers TH, D2, and DAT.
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2. Materials and Methods
2.1 Animal Protocols
2.1.1 General Care
	Adult (PND 70-74 at entry into study) and adolescent (PND 34-36 at entry into study)
male Wistar rats were used in this study. To reduce the risk of negative social interactions, and to
ensure consistency across manipulations, animals were singly housed beginning 3-4 days prior to
study entry. In the case of animals requiring transfers from Bioscience to the Psychology facilities,
animals were transferred and singly housed 7 days prior to study entry. Vivarium house lights
were maintained on a regular 12 hour light/dark cycle in both facilities, and the room controlled
for temperature and humidity. Food and water were provided ad libidum throughout the study
with the exception of the daily 6 hour period during which animals were in the VSA protocol (see
below).
2.1.2 Animal Restraint Stress and Behavioral Scoring
	All restraints were carried out 1.5-2.5 hours after onset of the light cycle, a time consistent
with low endogenous CORT levels. Restraint or exposure sessions were conducted in the animals’
home cages in the housing room using vented acrylic restrainers with adjustable closure slides.
Animal length and girth were assessed to ensure the restrainer selected for use did not impinge
upon any region of the body in order to reduce the possibility of pressure or pain stimuli from
contributing to the stress experienced. Animals were either restrained for 30 minutes per day for
14 days (repeated stress group - R), exposed to the restrainer for 13 days for 30 minutes per day
then restrained on the 14th day for 30 minutes (acute stress group- A), or exposed to the restrainer
for 14 days for 30 minutes per day (control stress group- C) (see Figure 2.1 and 2.2 for experimental
overview and time line, and Table 2.1 for animal allocations). All restrainers were removed from
the home cages at the end of the stress period to control for novel object presentation, and cleaned
daily to remove animal scent, fecal residue and urine.
	During restraint sessions in the final adult male cohort, animals were observed for 10
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Figure 2.2 Animal Allocation and Design
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Table 2.1 Animal Allocations for Studies

IHC
WB

Control
Adult

Control
Adolescent

Acute
Adult

Acute
Adolescent

Repeat
Adult

Repeat
Adolescent

PVH

6

6

5

6

5

6

NAcc

6

6

5

6

5

6

TH

4

5

7

6

6

8

D2

4

5

7

6

6

8

DAT

6

4

5

5

5

7

7

5

5

4

6

4

IVSA*

*Three control adult animals were placed into saline groups for activity comparisons in IVSA.
seconds every five minutes for locomotor activity during restraint. Activity scores of 1 were
assigned to animals observed chewing, struggling, or attempting to turn around in the restrainer
during the window of observation. Animals that were quiescent during observation were assigned
a score of zero. Scores were then tallied for each day to give a daily activity score and summed
across the duration of the 14 days to obtain a total activity score.
2.1.3 Catheter Construction and Patency Regimen
	Catheter construction was done in-house using an 11 mm 22 gauge catheter guide with 5
mm upper reveal. The lower section of the guide was bent into a “J” curve prior to tubing fitting
and the ends were smoothed and checked for flow using isopropyl alcohol. The main catheter
tubing (0.33 mm I.D. silastic) was softened in Citrisolv solvent prior to fitting over the lower portion
of the catheter guide with an additional length silastic tubing (0.64 mm I.D. ) acting as a protective
sheath to the line at the inlet juncture (Figure 2.3). Catheter guides and tubing were then affixed
to a 3.5-4 cm diameter circular mesh backing (Sefar Propytex 500 μm) using dental acrylic set in an
aluminum block mold. Once set, the catheters were removed from the mold and a small bead of

Sheath
(2cm)

Inlet
Acrylic

{

Silicone Hold-fast

Outlet Line
(14cm)

(4cm)

Mesh (4cm)
Figure 2.3 Catheter Construction Diagram
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clear silicone adhesive was applied as a hold-fast 4 cm from the end of the outlet tubing (Figure 2.3).
After allowing overnight curing, the catheters were tested for patency with ethanol and autoclaved
prior to implantation. Immediately before implantation, patency was assessed one final time with
sterile saline. Post-implantation, catheter patency was checked through administration of Brevital
(methohexital sodium) and animal muscle tone observed (Table 2.1). Daily flushes both before
and after IVSA sessions with 0.2 ml Timentin in heparinized saline were done to maintain catheters.
Animals that failed patency checks or lost patency during the study were excluded from statistical
analysis.
Table 2.2 Study Drugs, Administration Routes, and Dose
Compound

Provider

Purpose

Ketamine

Bionichepharma

Xylazine

Lloyd Laboratories
Vedco
Bimeda

Anesthetic/analgesic
Anesthetic/muscle relaxant
Anesthetic
Anti-inflammatory/analgesic
Antibiotic
Anticoagulant
Paralytic/patency
check
Anesthetic/euthanasia
Anesthetic maintenance
Addictive psychostimulant

Acepromazine
Flunixin meglumine
Timintin
Heparin
Brevital
Sodium Pentobarbitol
Isofluorane
Methamphetamine

Sigma
Vedco
Sigma

Concentration

100 mg/ml
1000 USP/ml
10 mg/ml

Dose

Delivery

50 mg/kg

I.P.

5 mg/kg

I.P.

1 mg/kg
2.5 mg/kg

I.P.
S.C.

200 μl
200 μl
200 μl

I.V.
I.V.
I.V.

100 mg/kg

I.P.

1.5-2.0% in O2
50 μg/kg/inf

Inhaled
200 μl infusions self-administered

I.V.

2.1.4 Surgery
	Anesthetic induction was carried out using intraperitoneal injection (1 ml/kg) of a cocktail
of ketamine, xylazine, and acepromazine (Rompun mix) (see Table 2.1). Upon induction, animals
were depilated and the surgical field prepared with alcohol and betadine to reduce infectious
particle load. A deep level of anesthetia was maintained with isofluorane (1.5-2%) in oxygen for
the duration of the surgery. Incisions were made starting below the scapula and extending 5-6
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cm (dependent upon animal size) parallel to the spine of the animal. A subcutaneous pocket was
created using blunt dissection to accommodate the catheter support mesh. Blunt dissection was
extended up over the shoulder and to the ventral portion of the neck to create a path for the
catheter line.
	Upon locating the jugular pulse, an incision 1-1.5 cm was made 900 to the line of the jugular
vein. At this stage, the catheter inlet was placed in the subcutaneous pocket and the outlet line
run subcutaneously over the right shoulder. The jugular vein was then isolated and a small incision
made in the vein to accommodate the catheter outlet line, now trimmed at a 20-300 angle to a
length appropriate for the run from jugular to heart. Once the catheter was in place, patency was
assessed via blood draw and sutured using non-absorbable suture line to tie below the silicone
hold-fast securing the line inside the vein, and again above the silicone hold-fast to the vein to
reduce movement of the catheter line. To ensure constriction of the catheter was not introduced
by sutures, patency was again checked after each suture. Cyanoacrylate glue was then used as a
final measure of securing the sutures and sealing the vein. Wound clips (Stoelting, Wood Dale)
were used to close the incisions at the neck and along the back, with sutures used to secure the
area immediately adjacent to the inlet protrusion.
Wounds were treated with a standard OTC topical antibiotic with lidocaine (Neosporin), and
Flunixin analgesic administered (Table 2.1) before removing the animal from isofluorane. Saline
was administered subcutaneously for hydration as needed (~3 ml). Heparin with Timentin antibiotic
(Table 2.1) was used to flush the catheter line prior to capping off with sealed tubing, and animals
were allowed to recover in home cages supplied with surgical bedding. Additionally, during the
first 45 minutes of recovery, half of the cage floor was warmed with heating pads on a moderate
setting, providing a region of warmth for recovery, and a cool region for the animal to move to
when warming was no longer desired. Animal observations and pain management were carried
out over the next three days as guided by protocol and Veterinary Services recommendations.
2.1.5 Intravenous Self-Administration (IVSA)
	Following three days of post-surgical recovery, catheter patency was assessed and animals
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were assigned to operant chambers. Food training was not used prior to introducing animals to
the chambers to avoid possible confounds that may arise from food and stress interplay, and to
minimize the time in between stress treatment and access to drug. The catheters were flushed
with heparinized saline containing antibiotic and drug concentrations adjusted per animal based
on the weights of the previous day. Tygon tubing (I.D. 0.020) encased in a coiled steel protective
line fitted with a swage to allow catheter inlet securement was connected to a micro-infusion
pump (Harvard Apparatus, Holliston) set to dispense 50 µl/s of solution upon press of the active
lever. Drug solutions in 20 ml syringes were placed in the pumps and pumps were used to flush out
ethanol solution (used to reduce risk of microbial contamination of the lines) and ensure no voids
were present prior to the animal being connected. Operant chambers (Med Associates, St. Albans)
were completely enclosed in white-noise providing, light-restricted cabinets, allowing control of
chamber lights (kept on for the duration of the study to synchronize with the animals’ schedule).
	The IVSA program was set to deploy an active (front) lever and an inactive (back) lever
simultaneously. Active levers were set to activate a 20 second cue light and dispense 200 µl of
drug immediately upon press followed by a 20 second time out period where further activity on
the active lever would not be rewarded with drug. This was done to minimize risk of overdose,
limiting METH intake to a maximum of 3 self-administrations per minute (150 μg/kg/minute or 54
mg/kg/session maximum intake). A session summary is provided in Table 2.2. An inactive lever
press provided neither drug nor cue light upon activation. All sessions were started 60-90 minutes
after vivarium lights switched on.
	Lever press data was collected and parsed out in 10 minute bins for the 6 hour duration
of drug availability. At the end of each session, the levers retracted and the house lights were
switched off. Animals were removed from their within 3 minutes of session end, catheters flushed
with heparinized saline and antibiotic, and end caps and protective inlet covers were replaced.
Animals were weighed to establish the concentration of drug required the following day, and
examined for general condition before being returned to the home cage. The chambers were then
cleaned, examined for required maintenance and all lines were flushed with ethanol in preparation
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for the following sessions. Animals that failed to meet a minimum threshold of performance were
excluded from data analysis.
Table 2.3 IVSA Settings Summary
Session
Length
360 min

Dispense
Time
4 sec

Dispense
Vol
200 μl

Time
Out
20 sec

House
Light
On

Stimulus
Light
Active Lever
Only

Stimulus
Light Time
20 sec

#Active # Inactive
Levers
Levers
1
1

2.2 Tissue Harvest
	Brain tissues were collected from C, A, and R animals to determine the effects of stress on
molecular markers associated with drug intake and reward. Two hours after onset of the stress
or exposure period on their final treatment day, some animals were lethally anesthetized with
sodium pentobarbital (see Table 2.1 for dosage). Immediately following decapitation, brains were
isolated, coronally blocked into four sections including one section encompassing the rostral-tocaudal extent of nucleus accumbens (Figure 2.4 and Figure 2.5), and rapidly frozen on dry ice for
storage at -800C. Separate groups of animals underwent transcardial perfusion; these rats were
A.

B.

C.

Figure 2.4 Section Demarcation for Nucleus Accumbens Enrichment for Western Blot
Panel A. Sagital view is shaded to denote the region of the nucleus accumbens. Panel B. Rostral-most extent of
the coronal section. Panel C. Caudal-most extent of the coronal section. Shaded regions denote incision lines
used to enrich for nucleus accumbens. Atlas images from Paxinos and Watson, 1998.
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Figure 2.5 Atlas Sections for NAcc and PVH

Posterior

Illustrated above are the four sections of NAcc selected for Fos immunopositive neuron counts as well as the six
sections of PVH. Gray shading denotes the structural boundaries used in counting. All samples were sectioned
at 30 μm. Images adapted from The Rat Brain in Stereotaxic Coordinates, Fourth Ed. Paxinos and Watson, 1988.

lethally anesthetized with sodium pentobarbitol two hours after the onset of their final treatment
and perfused with ~100 mls normal saline (0.85%) at 40C. This was followed by perfusion with
~500 mls 40C, 4% paraformaldehyde at pH 9.4, buffered with sodium tetraborate. Brains were then
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isolated and postfixed for 5 hours at 40C to continue passive exposure to the fixative. Brains were
then allowed to sink in potassium and phosphate buffered saline (KPBS) with 20% sucrose (18-24
hours, 40C) whereupon brains were blocked at the cerebellum and coronally either flash frozen in
hexane and stored at -800C until sectioning, or immediately sectioned at 30 μm on a freezing stage
tabletop microtome (Leica) in five series of five wells in 24-well plates with ~ 300 μl cryoprotective
solution (0.74% sodium phosphate monobasic, 2.73% sodium phosphate dibasic, 30% ethylene
glycol, 20% glycerol) and stored at -200C until used in immunohistochemistry.
2.3 Immunohistochemistry (IHC)
	Classic studies in neuronal activation use immunoreactivity with the immediate early gene
product Fos. This marker is well characterized, and demonstrates consistent performance in multiple
neuronal populations including neurons of the PVH under a number of stress conditions (excluding
hypertonic stress) (Seasholtz et al, 1988; Imaki et al, 1992; Hoffman et al, 1991; Kajaer et al, 1994;
Chan et al, 1993; Covenas et al, 1993; Kononen et al, 1992). This marker is further suited to our
purposes given evidence that Fos immunoreactivity co-labels well with CRF-expressing neurons in
the PVH (Chat et al, 1993; Seasholtz et al, 1988; Imaki et al, 1992). Thus, to investigate states of
activation within reward-associated structures of the brain, we surveyed across six sections of the
PVH and across four sections of the nucleus accumbens shell and core for Fos-immunoreactive
neurons (see Figure 2.3). Briefly, coronal sections containing these structures were rinsed twice
in KPBS for 10 minutes, treated with 0.3% hydrogen peroxide for 10 minutes followed by two 10
minute rinses in KPBS and treatment in 1% sodium borohydride in KPBS. This was followed by
KPBS rinses (on average, 6 X 10 minute rinses) and placement of tissue into a solution of blocking
buffer (2% normal goat serum (NGS) (Vector) and 0.3% Triton x 100 in KPBS) and rabbit-anti-Fos
antibody at a dilution of 1:25,000 (see Table 2.3 for antibody information). After 16-18 hours of
incubation in primary antibody solution at 40C on an orbital table (50 rpm), tissues were removed
and rinsed twice for 10 minutes in KPBS prior to incubation in biotinylated secondary antibody
(goat-anti-rabbit gamma globulin) at a dilution of 1:200 in blocking buffer followed by 1 hour of
room temperature incubation on an orbital table. The solution was again washed twice for ten
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minutes in KPBS followed by use of a solution of avidin DH and biotinylated horseradish peroxidase
H solutions contained in the standard Vectastain Elite ABC kit (Vector), using 1 drop of each reagent
per 10 mls of KPBS. This was then allowed to complex with the secondary-labeled tissue followed
by treatment in sodium acetate and subsequent nickel-enhanced diaminobenzadine (DAB) reaction
in the presence of β-D-glucose, glucose oxidase and ammonium chloride (Hancock, 1984). After
4-6 minutes of reaction, two 10 minute rinses in sodium acetate were followed by rinses in KBPS
and tissue sections were mounted on gelatin-sublimated slides. After drying, mounted tissue was
then sequentially dehydrated in an ethanol series and clarified in xylene prior to application of DPX
mounting solution and coverslip.
2.4 Western Blot Analysis (WB)
	For Western blots, unilateral sections of ventral striatum containing the nucleus accumbens
with an approximate wet weight of 4 mg were isolated as depicted in Figure 2.4. Briefly, using
the brain atlas and stereotaxic coordinates of The Rat Brain in Stereotaxic Coordinates Fourth Ed.
(Paxinos and Watson, 1998) for reference, coronal sections were made from freshly dissected brains
using a coronal 1mm matrix to block a 2 mm section encompassing the majority of the nucleus
accumbens in the rostral-to-caudal extent with the goal of capturing the Bregma coordinate region
from ~+0.70 - +2.20. These slices were further refined by making a midline incision followed by
an angled incision roughly perpendicular to the midline (Figure 2.4). Due to the high content of
dopaminergic markers (most notably DAT) in the dorsal striatum, removal of caudate putamen
was prioritized by this approach. However, the distribution of additional small ventral striatal
structures throughout the nucleus accumbens shell and core did not allow for consistent removal
of these structures. Thus our preparations included the following structures: anterior olfactory
nucleus posterior part, cell bridges of the ventral striatum, dorsal endopiriform nucleus, islands
of Calleja, nucleus of the horizontal limb of the diagonal band, lateral septal nucleus, median
forebrain bundle intermediate part, medial septal nucleus, piriform cortex, semilunar nucleus,
septohippocampal nucleus, olfactory tubercle, lateral stripe of the striatum, nucleus of the vertical
limb of the diagonal band, ventral pallidum. Isolated sections were placed in 500 µl of lysis
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buffer (TPER, Thermo Scientific) and 5µl of HALT protease inhibitor cocktail (Thermo Scientific),
and homogenized on ice using glass homogenizers until the tissue was completely homogenized.
Homogenates were then spun down at 5,000 rpm for five minutes, and supernatants collected for
analysis or storage at -800C.
Protein concentration was determined using the recommended protocol in the Pierce BCA
Assay Kit (Thermo Scientific, Rockford) for microplates. Protein samples were then adjusted to
ensure samples run contained 25 µg of protein in 20 µl volumes. All samples were prepared in
denaturing conditions using 4 µl sample buffer: 20% glycerol, 10% sodium dodecyl sulfate, 0.01%
bromphenol blue, in 1M Tris buffer. Protein samples for use in D2 and TH labeling were heated for
7 minutes at 700C; however due to complex formation at high temperatures, DAT preparations
were not heated prior to loading in pre-cast 10-20% gradient gels (Bio-Rad, Hercules). Stacking
current was 80 V for 20 minutes followed by 90 minutes at 100 V or until the tracking dye reached
~ 4 mm from the bottom of the gel. Gels were then transferred onto 2 µm polyvinyl difluoride
membrane soaked in 100% methanol prior to stacking the transfer layers. Membranes were then
removed and rinsed 3 times for 5 minutes each on orbital shaker in TBS (see Appendix I) and
blocked in a milk solution for two hours prior to introduction of primary antibodies (see Table 2.3).
Primary antibodies were allowed to bind over 20 hours at 40C with the exception of DAT which was
allowed 48 hours or longer to bind. Membranes were rinsed in TBS 3 times for 5 minutes then
block solution containing anti-actin was allowed to bind at room temperature for 2 hours followed
by an additional 3 rinses in TBS prior to the introduction of horseradish peroxidase-conjugated
antibodies in blocking solution (see Table 2.3). Secondary antibodies were allowed to bind for 2
hours at room temperature (TH, and D2 primaries) or for 6 hours at room temperature (DAT). The
membranes were then rinsed a final 5 times in TBS and chemiluminescent reagent was added and
allowed to react for two minutes prior to film exposures.
Table 2.4 Antibodies Used in Study
Type
10
10

Antigen
cFos
D2

System
Rabbit
Rabbit

Manufacturer
Calbiochem
Milipore

Cat #
PC38
AB5084P
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Conc.
1:25,000
1:2,000

Process
IHC
WB

Conjugation

10
10
10
20
20
20

DAT
TH
Actin
Mouse
Rabbit
Rabbit

Rabbit
Mouse
Rabbit
Goat
Goat
Goat

Santa Cruz
Milipore
Thermo Scientific
Southern Biotech
Southern Biotech
Vector

SC-14002
MAB318
PNA2066

1:500
1:2000
1:2000
1:2000
1:2000
1:200

WB
WB
WB
WB
WB
IHC

HRP
HRP
Biotin

2.5 Imaging, Cell Counts, and Densitometry
2.5.1 Immunohistochemistry
	Slides were analyzed through imaged using the 10X objective on a Zeiss Axioskop 40
Boundaries of structures were determined via reference landmarks in The Rat Atlas (Paxinos
and Watson, 1998) cross-referenced with nissl-stained series for the animals, and counts of
Fos-immunopositive neurons were conducted. Nucleus accumbens regions were surveyed from
Bregma level 1.20 mm to 1.70 mm and bilateral counts made. Paraventricular nucleus of the
hypothalamus regions were surveyd from Bregma level -1.30 mm to -2.12 mm (refer to figures 2.5
and 2.6).

A.

B.

Figure 2.6 Fos Immunopositive Sample Regions of Survey for NAcc and PVH
Representative section of Fos-immunolabeled tissue from A) NAcc (Bregma ~1.70 mm), and B) PVH (Bregma
~-1.70 mm) imaged at 5X magnification for purposes of illustration.

37

2.5.2 Densitometry
	Exposed Western blot films were scanned using a Kodak ESP 3250 model scanning bed at
a resolution of 1000 ppi. Resulting images were then analyzed after converting images to black
and white, inverting, and selecting band regions for histogram analysis in Adobe Photoshop CS6
(Adobe Systems Incorporated, San Jose)
2.6 Statistical Analysis
	For neuron counts and Western blot data, one-way ANOVA was used. Pairwise comparisons
were conducted between ages for the respective stress conditions, and within age groups between
Controls and Acutes, between Acutes and Repeats, and between Repeats and Controls. To examine
differences observed among stress conditions within one age, active lever presses (attempts to
self-administer METH) were analyzed using a two-way repeated measures ANOVA with stress as a
between group factor and days IVSA as a within-subjects factor. Pairwise comparisons were made
between Controls and Acutes, between Acutes and Repeats, and between Repeats and Controls in
all cases. Behavioral comparisons of age at time of stress were also made between corresponding
stress treatments using two-way ANOVA with age as a between subjects factor and days IVSA as
the within subjects factor. Tukey’s post hoc analysis was used in all measures.
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3. RESULTS AND DISCUSSION
3.1 Immunohistochemical Survey of Fos-Immunopositive Neurons
3. 1 .1 Use of Fos Immunopositive Label as a Marker of Neuronal Activation: Rationale and
Limitations
Using Fos immunoreactivity in the PVH as a means of assessing neuronal activation in
response to stress is well-established. It is not a direct measure of CRF secretion nor do Fosimmunopositive (Fos+) neurons exclusively co-express CRF. However, when stimulated by stress,
Fos+ neurons do reliably co-label CRF+ neurons regardless of the stress paradigm used with the
exception of high-salt challenge (Herrera and Robertson, 1996; Kovacs, 1998 [review]; Li et al,
1996; Chan et al, 1993; Wamsteeker et al, 2013). Thus, for a study that is not focused on the
neuroanatomy and characterization of specific neuronal populations, using Fos+ neurons as a
partial proxy for CRF+ neuronal recruitment circumvents the difficulties intrinsic to dealing with
currently-available anti-CRF antibodies which are plagued by high background and low sensitivity.
While this logic is more challenging to extend to the use of Fos+ in measuring neuronal activation in
the NAcc with specific respect to CRF or CRFR neurons, stress and subsequent glutamate elevations
(refer to Figure 1.5, Figure 1.6, see Figure 3.1) have been documented to elevate Fos in response to
both pleasant and noxious stimuli (Schwarzschild et al, 1997; Pecina et al, 2006; Faure et al, 2010).
Thus Fos+ is a marker suitable for measuring neuronal recruitment under conditions of stress and
reward, but less biased in representing specific subpopulations of CRF/CRFR co-localization in the
NAcc.
	This being said, the neurological responses to stress in non-adult models are less wellcharacterized. While, this survey offers the field novel information which may complement the
serological studies done to date on circulating CORT and ACTH for adolescent rodents (refer to
Figure 1.9), it does not specifically address issues of CRF co-expression, nor does it specifically seek
to characterize the neurons with respect to any other secondary marker, and care should be taken
in any conjectures regarding the adolescent data sets.
In general, the relationship between expression of Fos+, downstream signaling and
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transcription events, and the actions of CORT and CRF in eliciting these cascades forms an
interesting overlap with GABAergic and glutamatergic signaling, dopamine production and efflux,
calcium influx, dopamine receptor binding efficiencies, generation of opioid receptor ligands,
intracellular oxidative states, monoamine transporter function, and ΔFosB accumulation and
subsequent suppression of Fos production (Parnaudeau et al, 2014; Robison et al, 2013; Besheer
et al, 2014; Sun et al, 2008; Bertran-Gonzalez et al, 2008; Mombereau et al, 2007; Schoffelmeer
et al, 1995; Djouma et al, 2006). A small portion of this is mapped out for NAcc in Figure 3.1, and
even within this restricted window of interactions, it quickly becomes apparent how stress and
dopamine systems interrelate in both direct and indirect fashion. Furthermore, given the delicate
nature of system negative regulation, small disruptions have the potential to throw the entire
system out of balance, especially considering the persistent nature of phosphorylated ΔFosB pools
that accumulate when the system is activated repeatedly as it is in both chronic stress and chronic
drug use.
3.1.2 The NAcc Shell Exhibits Greater Immunoreactivity than the NAcc Core
	Analysis of Fos-immunopositive (Fos+) neurons in the NAcc revealed several key differences
in the expression of Fos in the shell region compared to the core. The largest differences in
response to stress were seen in the shell. This is consistent with the findings from multiple studies
that showed preferential activation of the shell versus the core in response to both rewarding
and emotionally aversive stimuli (Lemos et al, 2012; Faure et al, 2010; Faure et al, 2008; Fuchs
et al, 2008; Goto and Grace, 2008; Ito et al, 2008; Pacchioni et al, 2007; Pecina et al, 2006). In
adolescents, there was a nearly-significant main effect of section from which Fos counts were
taken [F (3, 42) = 3.597; p = 0.056]. However, the main effect of stress treatment [F (1, 14) =
10.604; p = 0.002] and section interaction with treatment [F (6, 42) = 3.117; p = 0.047] were both
significant indicating that not only the type of stress applied shifted the expression of Fos+, but this
change was also influenced by which coronal section was being surveyed. Using Tukey’s post hoc
analysis, differences emerged among adolescent stress responses in the shell overall (Figure 3.2
Panel A).
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	The anterior-most sections through the NAcc of

repeated adolescents (RO) had a

significantly lower number of stress-induced Fos+ neurons than repeated adults (RA) for those
same sections (Figure 3.2 Panel A). Comparisons of total Fos+ counts between age groups also
showed a main effect of age [F (1,27) = 7.613; p = 0.01] but a marginal treatment X age interaction
[F (2, 34) = 3.084; p = 0.057]. In post hoc analysis of the total Fos+ count for sections surveyed,
strong differences were observed in acute adolescents (AO) versus acute adults (AA), and between
AO and RO (Figure 3.2 Panel B).
In the NAcc core, Fos+ counts were low overall compared to values attained in the shell.
Again, this is consistent with a reduced involvement of this structure in responses to emotional
stress. Adolescents showed no main effect of series, but did demonstrate a main effect of
treatment [F (1, 14) = 6.463; p = 0.010] with significant differences in AO versus control adolescents
(CO) and RO (Figure 3.2 Panel D). As with adolescents, for adults, only the treatment condition
exhibited significant main effect [F (1,13) = 13.166; p = 0.001]; however a main effect was seen in
age [F (1,26] = 16.006; p <0.001] and in post hoc analysis, AO and RO both exhibited significantly
lower Fos+ counts by section than their adult counterparts (Figure 3.2 Panel C). In contrast to
the shell in RA versus control adults (CA), wherein the anterior-most section exhibited significant
elevations in Fos+ cells but showed no significant differences when the total was summed from
all sections surveyed, the core totals from RA were significantly elevated versus CA values, yet this
significance was not maintained when examined by section. Thus, the entire NAcc core that was
analyzed appears to uniformly contribute to chronic stress responses, whereas the shell exhibits an
anatomical preference in terms of the location of cells engaged in chronic stress responses through
these sections. While this data is intriguing, without specific tracing studies or co-localization
mapping through these and through more anterior and posterior sections of the structure, little
more can be inferred.
3.1.3 Interpreting the Data: Stress-Induced Fos+ Neurons of the NAcc Shell and Core
While the section-level analysis provides a limited view of events in the NAcc, this region
has been carefully selected to sample areas populated with neurons that respond to both stress
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Figure 3. 2 NAcc Fos Immunopositive Neuron Counts for Adolescent and Adult Males
Counts per 30 μm section of the NAcc from the rostral-to-caudal extent of the four sections examined are listed
from left to right of shell (Panel A) and core (Panel B). All data represents the group mean. Error is expressed
in SEM. For total NAcc shell (Panel C) and core (Panel D), two-way ANOVA was conducted with Tukey’s post hoc
analysis. Significance versus Control: * = p < 0.05; ** = p < 0.005. Significance versus Repeat: # = p < 0.05; ## = p
< 0.005. Significance versus Adult: † = p < 0.05; ‡ = p = < 0.005. Control (C) = White. Acute (A) = Black . Repeated
(R) = Gray.
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cues and hedonic stimuli. DAergic neurons under regulation of GABA and glutamate, and CRFR+
neurons are both represented, and have been shown to correspond to Fos+ elevation arising from
stress and reward, in addition to being associated with motivated behaviors ranging from defensive
locomotion in response to stressful stimuli to hedonic responses to a pleasant stimulus (sucrose)
and increased feeding (Faure et al, 2010; Pecina et al, 2006, Rodaros et al, 2007; Swanson et al,
1983; Wamsteeker et al, 2013).
In adolescent NAcc shells, while AO did have strongly significant increases compared to
CO and, to a lesser extent, RO, fewer neurons were recruited versus their adult counterparts
despite having similar neuron density. This prompts the question of whether the adolescents
are responding less avidly and adversely to acute stress. Interestingly, the anterior-most sections
(which are more strongly correlated with motivated behavior in the face of hedonic stimuli) in
repeatedly stressed adolescents have far less neuronal activation than do the adults. In prelude to
discussion regarding the behavior of adolescents in METH self-administration, the observed failure
to escalate in this group may be attributable to changes in the responsiveness of neurons within
this region to the rewarding stressor of drug.
	The overall Fos+ profiles of the NAcc core still follow the pattern of elevation in response
to acute stress and a return to near-control values under chronic stress. However, the differences
between the RA and RO and AA and AO are significant. While the core is less associated with the
rewarding effects of drug, it is essential in cue-association and motor planning, thus still maintaining
a role of importance in addiction (Kelley et al, 1997). However, given that repeated Fos induction
results in a gradual increase in phosphorylated ΔFosB which, in turn, attenuates the ability for Fos
to be induced (Figure 3.1) stronger expression of Fos may indicate either a disruption in FosBassociated functions, or that different subpopulations of neurons are responding to continued
challenge. It should be mentioned here that immunofluorescent surveys were attempted for
FosB and Fos co-localization in the initial stages of the study, but due to the perfusion protocol
employed, sufficient signal-to-noise could not be attained; however, future studies may benefit
from minor protocol adjustments in order to accommodate this survey.
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3.1.4 The PVH in Adults Displays Greater Response to Acute Stress than Observed in Adolescents
Fos+ expression in response to acute and chronic homotypic (unvaried) stress for both
adolescents and adults in the PVH follows a classic pattern: a large response to the acute stress
with diminished responses, or habituation, as a consequence of repeated exposures. Thus, the
overall curve of the graph for total Fos+ counts in the structure for both adolescents and adults was
not unexpected. Interestingly, while main effects were seen in both adolescents [F (2, 7) = 7.691;
p = 0.017] and adults [F (2, 12) = 19.093; p < 0.001], the responses by section within AAs were
far more robust and uniformly distributed than that seen in AOs (Figure 3.3). Furthermore, while
there were no main effects of section for adolescents assessed by two-way ANOVA, there was both
a main effect of section [F (5, 60) = 6.221; p = 0.008], and an interaction of treatment and section [F
(10, 60) = 2.311; p = 0.023] observed. By examining Fos+ expression in both NAcc and PVH in this
higher resolution format, the differences between adolescent and adult stress-induction of neural
activity emerge.
	As an aside, it was interesting to note that for both NAcc and PVH the standard error of AO
was much higher than of AA, and in fact, while not as dramatic, higher error was observed among
all treatment groups in adolescents versus their adult counterparts. From a research perspective,
while this could be attributable to random variation in animal responsiveness to stress, it should
be emphasized that rat adolescence is a time of rapid change, and exceedingly compressed in
its window of time compared to humans. Within a span of days, the neurological underpinnings
of stress and motivation are shifting from a juvenile to adult state (refer to Figure 1.9 in the
introduction). Thus, when examining the individual animals included in this survey, the lowest
Fos+ counts were observed in the youngest animals of the age bracket, but did not meet the
criteria for exclusion. Thus, when designing studies using adolescent rats, a ±2 day margin may be
too generous, and has the potential to introduce confounds to the study.
3.1.5 Interpreting the Data: Stress-Induced Fos+ Neurons of the PVH
	The total Fos+ count profiles are not significantly different in adolescents (~PND 50) versus
adults (PND 76-82) (Figure3.3) however, there are subtle shifts in Fos+ distribution progressing
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from the anterior to the posterior of the structure. Analysis of coronal sections in acute versus
control revealed a less uniformly robust increase in Fos+ neurons in adolescents compared to
adults. Furthermore, RO exhibited significant difference from acute only in the caudal-most section
whereas significance was distributed throughout the PVH in adults for these groups. This suggests
one of two possibilities in adolescents: 1) that neurons involved in the initial response to stress in
the anterior portions of the PVH are not highly recruited and warrant further characterization, or
that 2) adaptation to chronic predictable emotional stress is not as efficient as in adults. Given
the lack of significant difference in Fos+ neurons between controls and repeated restraint groups
seen in both ages, and given the lack of pervasive statistical difference from controls among acute
adolescents, the first interpretation is more likely. General contributions from the survey of this
structure are to establish 1) that rats experienced stress during the restraint treatment, 2) that
adolescents did not exhibit radical departure from the pattern of attenuated Fos+ in RO, 3) a
baseline pattern against which NAcc comparisons could be made under the assumption that PVHsourced CRF may be partially involved in stress-associated neuron activation observed.
3.2 Western Blot Data for TH, D2, and DAT Show No Significant Differences Among Groups
	Stress has been documented in many studies to influence the production and function
of dopaminergic componentry including the downregulation of D2, and differential effects on
TH in males versus females. Thus, to ascertain if stress altered the expression of key markers
in the dopaminergic pathway, terminating in the NAcc, NAcc-enriched preparations of coronal
slices were assessed via Western blot conducted under reducing conditions. The results were
somewhat surprising given our initial hypothesis that changes in protein expression resultant
from stress treatments would be observed based on the findings of Lucas et al (2007) wherein in
situ hybridization demonstrated shifts in striatal D2 and DAT. While anticipating some differences
arising from electing to evaluate protein expression in our study in lieu of mRNA expression, no
significant differences were observed (Figure 3.4). In each group, fold-induction of the protein
determined through densitometry, exhibited no main effects of age [FTH(1,38) = 1.086; p = 0.305,
FD2 (1,38) = 2.068; p = 0.160, FDAT (1,31) = 0.759; p = 0.392] or treatment [FTH(2,38) = 1.392; p =
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Figure 3.4 Fold Induction of Protein Markers TH, D2, and DAT in Adolescent and Adult Males
Above, are the fold-induction values obtained through densitometric analysis of Western blots of NAcc-enriched
preparations from the right hemisphere. On the right, sample blots representing each of the conditions are
presented. Data is drawn from triplicate replicates for each sample. All samples normalized to actin. Molecular
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0.263, FD2 (2,38) = 0.21; p = 0.812, FDAT (2,31) = 0.819; p = 0.452]. In pairwise comparisons of age
within stress groups, no differences were observed, nor were there differences for stress treatment
comparisons within age groups.
While TH exhibits little change beyond rapid transient increases or decreases in healthy
neurons, even the transient increases observed in published studies of enzyme expression after
stress treatments were not observed (Palkovitz et al, 1975). This may be attributable in part to a
poor selection for tissue harvest time in relation to stress termination; however, given the age of the
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adolescents at time of harvest, among controls, TH expression would be expected to be lower than
control adults. This was not the case. Also, given the role of D2 in blocking the phosphorylation
site at Ser 40, it is possible that the interactions rather than the expression of these dopaminergic
markers are altered under stress conditions (Lindgren et al, 2001). Initial exploration of this
question could be conducted through the use of antibodies specific for phosphorylated TH at the
Ser 40 residue.
	Furthermore, with respect to D2, several studies suggest that stress, rather than changing
the level of expression of dopamine receptors, merely alters the binding efficiencies of the
receptors (Ito et al, 2000; Henry et al, 1995; Papp et al, 1994; Tomic and Joksimovic, 1991). It is,
therefore, not unprecedented that receptor levels remain static yet the overall performance of
the dopaminergic reward pathway still exhibits signs of effect. Though, as previously discussed,
the role of stress hormones in setting the release thresholds for dopamine transmission suggests
that alterations brought on by stress treatments are occurring at earlier levels in the hierarchy of
dopamine regulation, and not due to the total expression of these dopaminergic markers.
With respect to DAT, the oxidative state of the neuron under stress can induce complex
formation in DAT. Total protein remains unchanged, but protein function may be severely damaged
and non-reducing conditions that would allow us to observe the complexed species of DAT were
not used in this study. Thus, in terms of experimental design, certain flaws must be acknowledged.
While a great deal of information can be gained from Western blots, it is 1) a snapshot and therefore
vulnerable to inconsistent results as a function of choosing a time poorly, and 2) a non-discriminating
assay. In preparation of total proteins, no synaptosomal or membrane-associated enrichment steps
were taken and gels were run under reducing conditions which does not protect DAT complex from
breaking back down into component DAT. Thus proteins observed may have been in a cellular
compartment or a state of post-translational modification that interferes with function, but still is
indistinguishable from functional protein. However, this should not overshadow the fact that 1)
serotonergic and noradrenergic systems are also affected by stress, and may contribute to drug
vulnerabilities 2) other regions of the brain not surveyed here also contribute to the regulation
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of rewarding effects , perception of noxious (stressful) stimuli and motivated behaviors and may
exhibit greater sensitivity of response with respect to protein expression 3) stress hormones can
significantly alter the innate thresholds required for dopaminergic transmission and these effects
do not hinge upon the downstream expression of the markers examined.
3.3 Analysis of Behavior for METH Self-Administration
While the molecular data for this study were not conclusive, neuronal activation profiles in
the PVH in response to restraint stress did demonstrate similar elevations among acutely stressed
animals and decreases among repeatedly stressed animals relative to acute: a function that is linked
to neuroplasticity in the face of chronic challenge. This general pattern extends to the NAcc shell,
and, to a lesser extent, the core, and is recapitulated in the adolescent groups. However, with a lack
of difference in dopaminergic marker expression among the groups, the nature of the neuroplastic
events are still elusive. The question remains: does stress impact behavior? Shifting focus from
molecular mechanisms and neuroanatomy, we return to this practical question, in keeping with
the goal of this research: to determine if stress fundamentally alters response to METH. Following,
are the results of 21 sessions of 6 hour drug access. The duration of access was selected based on
the findings that, even though METH acquisition is highest in the first 60 minutes of drug access,
escalation is only observed in longer (6 hours) versus shorter (1 hour) access windows (Kitamura
et al, 2006). The study length (number of IVSA sessions) was determined by observations made
during previous studies in our own laboratory of overall animal health when self-administering
METH and the ability to sustain catheter patency.
3.3.1 An Overview of Acquisition
	To assess measures of escalation, the number of active (METH-dispensing) lever presses
is presented in Figure 3.5. Panels A and B show the daily number of lever presses for adolescents
and adults for the duration of the study. A distinction, however, must be emphasized between
active lever presses and actual drug received. A time-out period after successful drug delivery was
in effect which prevented further active lever presses from dispensing METH for the 20 seconds
following. Thus, there are discrepancies between the dose of METH acquired versus the actual
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attempts made that prevent use of dose (mg/Kg) values or rewarded presses as a direct measure
of escalation. With no topics addressed in the post-METH status of these animals, dose is less
significant to incorporate in in-depth analysis than behavioral metrics. Dose data is used in analyses
to determine its function as a potential predictor of future lever responding in later sections.
In a repeated measures ANOVA, Adolescent-stressed groups, had a main effect of day [F
(20, 220) = 2.116; p = 0.005]; however significant differences from early values in the study were
not observed in post hoc analysis. No main effect was present for treatment [F (2, 11) =0.801; p
= 0.797], nor were interactions of day and treatment observed [F (20, 40) = 0.852; p = =0.453].
These findings contrasted with our initial predictions of stress during adolescence providing a risk
factor toward addition, though, admittedly in the survey of neurons activated in the PVH and NAcc
by stress, the effects of repeated stress appeared to restore activation profiles to that of controls,
and the presences of reduced responding among acutes suggests that the stress that we applied,
while capable of recruiting neurons, did not stimulate the animals to the same degree. In contrast,
adult-stressed groups had a main effect of day [F (20, 300) = 11.853; p < 0.001] and of treatment [F
(2, 15) = 5.50; p = 0.016], but no interactions between day and treatment conditions. Observation
of significant differences from the first day’s intake was seen starting at the study midpoint and
continued through the final days of the study, indicating escalation (Figure 3.5 Panel B), and the
repeatedly stressed groups exhibited multiple days of significantly higher drug intake versus
controls, in keeping with our hypothesis. Thus, at first glance there is a disconnect between the
failure of stress to elicit changes in the dopaminergic markers assayed and the behavior displayed by
repeatedly stressed adults; however, neurons in the NAcc are clearly stimulated under conditions
of acute stress, and even remain elevated in the NAcc core after repeated treatments suggesting
persistent sensitivity to the stress in this structure. This would suggest that the mechanism of
stress-induced drug sensitivity lies not in elevations or reductions of proteins TH, D2, and DAT, but
reside in more functional aspects or within the mechanisms governed by stress hormones and
their receptors.
	As to the differences seen in adolescents versus adults, both in failure of stress to elicit
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any vulnerabilities to METH addiction, and in the failure for adolescents to escalate intake by
the end of study, part of this may be attributable to the developmental differences exhibited by
certain components of the stress and dopaminergic componentry during the stress paradigm
and subsequent drug exposures (Figures 1.9 and 3.6). By the start of METH IVSA, rats that were
stressed as adolescents were recovered from surgery by ~PND 54. While adolescent-stressed rats
at this age are nearing the standard age of adulthood (PND 60) there is still ongoing maturation of
the dopaminergic system until ~PND 70 (Figure 3.6). The duration of METH IVSA for these groups
spans the end of the adolescent period to the early stages of stabilization in the dopamine reward
pathway, making the groups neither fully adolescent nor fully adult during the majority of their
drug-taking experience, and developmental processes alone may account for the overall low and
consistent administrations observed (Figure 3.6). Adolescent-stressed rats are ending METH IVSA
before adult-stressed animals, and this small offset in age between adolescent-stressed and adultstressed animals when starting METH IVSA, warrants caution in drawing any sweeping conclusions
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Figure 3. 6 Study Age Distribution--A Failure to Overlap
Dark brown covers the region of adolescence during which the stress paradigm occurs. Light
brown regions denote the METH IVSA portion of study. Shades of gray are similarly distributed for adults. Region of age overlap occurs ~PND 70-83 but do not share a common protocol
during that window.
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between the two age groups. One further caution must be taken as the animals in our study
were singly housed starting ~6 days prior to study entry. While this was done to control for any
adverse interactions among rats that may occur in group housing situations, the fact remains that
rats are social animals and isolation represents a stress in and of itself. Adults are more resilient
to social stressors but adolescence represents a time of heightened sensitivity to social stressors
(Spear, 2000; Nelson et al, 2005; Vidal et al, 2007; Spear, 2012; Bozarth et al, 1989; Moore et al,
2014). As such, while mechanisms may exist which impart a certain protection against addiction
in adolescence through early adulthood in our model, it is difficult to tease this out in the face of
potentially having introduced a profoundly different stress experience to our adolescents. In this
regard, mechanisms that presage anhedonia may be responsible for the flat rate of drug intake, and
the general observances during animal handling of reduced responsiveness and righting reflexes
displayed by these animals versus their adult counterparts.
3.3.2 Refined Analysis of Drug Intake During the Window of Access
While daily totals for active lever activity provide a gross measure of overall escalation, data
collection for the 6 hour period takes place on a more refined scale. Collected in bins of 10 minutes,
this information offers the opportunity to see the ebb and flow of acquisition attempts across a
long period of time allowing us to see periods motivated drug seeking marked by increased lever
activity and satiety indicated by periods of low acquisition attempts. This allows us to overlay a
time course onto the known measures stress, desire, and satiety as addiction progresses. Visual
representation of this data in the form of heat maps (Figure 3.7) provides a means of rapid and
intuitive evaluation of an otherwise daunting data set. Figure 3.7 provides an overall assessment
of activity across 21 days (rows) and 36 10-minute bins (columns starting at the first bin) for adults
and adolescents across all conditions. On the right, data from both the first and last hours in IVSA
have been isolated to highlight two critical time points in METH IVSA that yield radically contrasting
profiles. One consistency among groups readily stands out. After the first day of IVSA, lightest
shades (the highest drug acquisition) occurs within the initial three bins (30 minutes) of drug
access which fits with the model of binging following a forced abstinence.
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Above are behavioral heat maps showing active lever presses across 21 days of IVSA (left to right) during 36 10
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	Recalling the general progression of meth metabolism, the 18 hour abstinence extends
beyond the pharmacological half-life of METH in rats (and humans) but stops shy of full drug
clearance. Peak appearances of withdrawal symptoms (including drug craving) and behaviors
(including measures of anxiety and anhedonia) are marked within the first 24 hours of abstinence.
Thus, when looking at the bin data for groups, regardless of the overall activity on the active lever,
the animals seek out METH with avidity, indicating that low daily lever presses do not correspond to
drug aversion, that METH is providing animals with a rewarding (or at least alleviating) experience,
and that, to this extent of the definition, there is a certain level of drive to obtain the drug exhibited
in all cases.
	The depth to which that band of high activity in the first hour progresses begins to highlight
differences among the groups. Within adults, first hour lever press after the first bins progresses
from low activity in the first week to progressively higher activity in the second and third week for
CA and AA. However, RA displays immediate high activity on the active lever that is maintained
with relative consistency throughout the first hour. In viewing the last hour, CA appears to have
graded steps across the study duration, gradually increasing activity seen in the final hour to
levels approaching that of RA. In AA, the jump from low to high activity in the last hour occurs
after the first week of IVSA, and again, RA appears to be an “early adopter” of increased drug
intake. Viewing the full distribution of activity, CA has a period following the first hour of relative
quiescence with a sudden jump to increased lever pressing near the midpoint of the access window
during the final week of IVSA. The time of decreased activity falls within the 2-4 hour window in
which the euphoric effects of METH are experienced and aligns with patterns of METH-induced DA
outlined by DiChiara and Imperato (1998) wherein a peak of dopamine release is observed within
the first half hour after administration followed by a radical decrease ~90 minutes thereafter and
continuing to fall to baseline over the next three hours. It would follow that as the rewarding effects
fade, self-administration would resume. This line of reasoning would also suggest, based on the
progression from low activity in the last hour to progressively higher rates of last-hour acquisition,
the maintenance of reward progressively diminishes with repeated METH exposure. This motif is
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lost in AA, wherein a sharp demarcation exists between persistence of low and of high acquisition
after the first hour. This, coupled with the almost-immediate steady rate of activity seen in RA
suggests that stress of this nature may influence the ability to achieve or maintain satiety, thereby
driving the escalation seen in addiction.
	The adolescents offer more of a challenge to interpret. The first hour of IVSA does show
high activity on the active lever consistent with behavior displayed by adults. Given the failure
for adolescents to escalate, this behavior addresses concerns over the METH dose. The behavior
would suggest that the does selected is neither too high and thus aversive, nor too low and unable
to elicit sufficient reward to drive avid early response after 18 hours of forced withdrawal. However,
in the subsequent bins, adolescents displayed relatively sporadic self-administration of drug along
the bin axis. Interestingly, in the second week of IVSA for RO, there appears to be an increase in
active lever responding that then returns to an erratic distribution of activity in the final week.
In attempts to address the cryptic appearance of this surge in activity, the age of the animal and
their developmental stage should be examined. In Figure 3.8, we see an interesting intersection
of events that approximately spans the period of heightened activity. Here ACTH under normal
unstressed conditions is found to be in rapid decline during the time corresponding to the start
of increased METH acquisition in repeatedly stressed animals. The termination of the activity is
enticingly concurrent with the plateau of TH.
	Under normal, unstressed, non-social isolation conditions, TH in adolescents should be
lower than that of adults: a phenomenon not observed among our adolescents in Western blots.
Furthermore chronic stress conditions in adolescents showed lower neuronal recruitment overall in
both PVH and NAcc, offering the possibility of altered responsiveness in either stress initiation or in
negative regulation of the HPA axis of which ACTH is a part. The potential of our stress to introduce
an alteration in reward responding during two surges in neurotrasmitter and neurohormonal
development, suggests that there may be a transient period of vulnerability toward METH that
chronic stress may facilitate. It has been demonstrated that chronic stress in early life results
in long-term deficiencies in ACTH levels which may introduce a transient relief from suppressive
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effects of HPA axis products though the mechanisms underling the proposed correlation between
TH levels, at PND 70 and the termination of increased drug acquisition are somewhat murky given
the limitations of our current study (Juruena, 2014; Lattin et al, 2012; Renard et al, 2007, Aguilera
et al, 1996 ). In sum, the chronic stress condition appears to have a temporary window of effect, in
increasing drug acquisition, however does not appear to persist into early adulthood. Furthermore,
the social isolation stress applied during adolescence may contribute to an overall anhedonic state
and protocols in future research should be adjusted accordingly.
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Figure 3. 8 Overlay of Stress and Dopamine-Reward Development with RO Heat Map Data

3.3.3 The Drug Dose Attained Does not Affect Drug Acquisition on the Following Day
	Robust METH IVSA behavior and strong group differences among adults shifted focus toward
a more in-depth investigation of potential contributing factors. Molecular and behavioral responses
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to METH can be dose-dependent and exhibit both a minimum dose required to elicit reward and
escalation and a maximum threshold beyond which aversion is experienced (Cunningham et al,
1992; Masukawa et al, 1992; Richards et al, 1999; Kitamura et al, 2006). A simple linear regression
was applied to the actual dose of METH acquired versus the active lever increase or decrease
observed on the following day of all individuals within each treatment group (Figure 3.9). The
R-squared values for all groups were < 0.2 suggesting little correlation between drug intake and a
subsequent increase or decrease in active lever performance.
3.3.4 Experiencing Time-Out on the Drug Lever Does not Correlate to Higher Inactive Lever
Response
	Given the inclusion of a time out period of 20 seconds after a press on the active lever
delivers a METH dose, the potential for unrewarded lever presses introduces the possibility of
aberrant lever behavior including increased presses on the inactive lever. Averages across group
for each bin of data collected during the entire study were used to obtain the values for time
out presses (Figure 3.10 Panel A), rewarded presses (Figure 3.10 Panel B) and the inactive lever
responses corresponding to data of subsequent bins. In plotting the data for time out activity
against subsequent bins for inactive press, there is no significant correlation which would
indicate unrewarded presses result in randomized lever selection. Neither does an increase in
the amount of METH received (rewarded press) presage an increase or decrease in inactive lever
press as a function of increased locomotor responses leading to non-specific (accidental) or nongoal-associated lever responding. However, without secondary measures that specifically test
impulsivity or compulsivity, it is difficult to apply specific interpretations to the data.
3.3.5 Struggle Observed During Restraint Stress May Predict Subsequent Behavior toward METH
Due to early indications of RA to have increased METH self-administration, a subsequent
cohort of RA rats was carefully monitored during the duration of restraint. While scoring methods in
the survey were a crude and binary metric (please refer to section 2.1.2 in Materials and Methods)
a pattern did emerge from the overall assessment of animal activity during restraint stress that in
simple linear regression correlated to the activity of not only the active (Figure 3.11 Panel A), but
59

Next-Day Active Lever Presses
Next-Day Active Lever Presses
Next-Day Active Lever Presses

300

Control Adult

10

R² = 0.1022

-300
300

Acute Adult

R² = 0.1024
10

-300
300

Repeat Adult

10

R² = 0.1076

-300
Dose METH (mg/kg)

Figure 3. 9 The Effects of Prior METH Dose on Next-Day Acquisition Attempts
Data displayed are non-averaged points. Each treatment group’s individuals have the daily change in active
lever response (increase or decrease) plotted verses the preceding day’s dose of METH.

60

35
R² = 6E-05

Inactive Lever Press

A.

0

B.

30

Time Out Presses

35

Inactive Lever Press

R² = 0.0012

0

Rewarded Presses

30

Figure 3.10 The Effects of Pressing during Time Out and of METH Dose on Next-Bin Inactive
Lever Presses
Group means per 10-minute bin for the study duration are displayed. R-squared values from simple linear regression are listed. No direct correlation between prior bin activity and subsequent inactive lever responses can
be drawn. Averages O = Control; Δ = Acute. X = Repeated.

61

also the inactive (Figure 3.11 Panel B) lever. This preliminary data has the disadvantage of small
sample size (n = 6), though from two different litters. The initial group of animals undergoing
behavioral observation was slightly larger (n = 9), however only 6 rats met requirements for study
inclusion and therefore, the remaining 3 were not included in the analysis. Animal behavior was
not associated with a specific litter.
While replication of this experiment is needed before firm conclusions can be drawn, the current
data set would suggest that more targeted drug acquisition behaviors indicative of goal-seeking
and learning (be it declarative or associative) might be predicted by the level of struggle observed
in restraint stress. Whether this indicates that a fundamental state of the individual exists
corresponding to both focused METH acquisition and to persistence of struggle, or if the stress
and response thereto shape future responses to METH is unknown. Given that low persistence of
struggle corresponds in these data to reduced METH acquisition and higher rates of inaccuracy,
the functions of anhedonia, cue-associated learning, and goal directed behavior toward addictive
substances becomes another question for future investigations of risk factors.
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values from linear regression are provided on the graph.
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4. Conclusions and Summary
4.1 Assessing the Big Picture
	The purpose of this study was to determine if a chronic or an acute emotional stressor
experienced during a particular phase of life is capable of influencing the path of future drug exposures toward a course of addiction. Using a strong emotional stressor (restraint stress) in a rat
model, we accomplished the following:
1. We evoked a stress response that could be measured by counting activated neurons and that,
with chronic administration manifested neuroplastic changes in stress and reward nuclei of the
brain.
2. We observed that the responses to stress in adolescents, while producing similar patterns of
neuron activation, does so with significantly less robustness and shows some differences in
anatomical preference of recruitment from the rostral to caudal extent surveyed.
3. We confirmed that food training is not necessary to establish robust and directed lever pressing for METH, which gives future researchers the freedom to establish new time lines for experimental manipulations and observations.
4. We established that the total protein expression for the METH-sensitive markers TH, D2, and
DAT does not highlight the mechanism behind observed behavioral differences in METH IVSA
for stressed groups versus non-stressed controls, or for adults versus adolescents, and we
suggest that other systems of signaling or additional metrics of function should be assayed in
future studies.
5. We established that the differences observed between adolescents and adults in neuron
recruitment are translated to METH self-administration wherein responses are generally lower
for adolescents, though not the manner in which these observations are related.
6. We discovered that among chronically stressed adolescents, the pattern of METH acquisition
may be reflective of developmental events that are disrupted by stress and may warrant
investigation from the perspective of anhedonia and depression.
7. We demonstrated a method by which long-term neurohormonal and neuroanatomical trends
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can be mapped onto IVSA data to facilitate the study of the adolescent age group which is still
underrepresented in the literature.
8. We observed measures of activity and struggle during restraint and found a correspondence
to more targeted METH acquisition suggesting a root mechanism that warrants further
investigation with more stringent experimental conditions.
9. Finally, we answered our initial question and found that:

Adolescent chronic stress does not appear to be a sustained risk factor for addiction in early
adulthood, but rather a transient risk factor. Adult chronic stress does appear to be a risk factor
in escalating drug use.

	Numerous studies are required to further support many of the findings herein. New studies
that probe some of the questions generated by this research, including extending adolescent IVSA
to observe long-term behaviors toward drug that more closely parallel behavior observed in adultstressed models. Furthermore, investigations of the measures of struggle in adults as a means of
predicting future behavior toward drug may help develop a behavioral metric for the purpose of
pre-screening animals in the lab setting, and for risk assessment within the medical and social work
communities.
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Appendix I
Standard Solutions List
I.

Histology and General Purpose

Antifreeze
•

1L MilliQ water

•

1.58g Sodium Phosphate (monobasic)

•

5.46g Sodium Phosphate (dibasic)

•

Mix well

•	Add 600ml Ethylene glycol
•

400ml Glycerol

•

Mix well

•	Store at 40C

DAB
•

5 mg/ml DAB (2.5g)

•

500ml MilliQ water

•

Mix well

•	Aliquot into 1ml tubes
•	Store in -200C

KPBS (0.02 M)
•

1L MilliQ water

•

19g Potassium Phosphate (dibasic)

•

2.25g Potassium phosphate (monobasic)

•

45g NaCl
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•

Mix well on stir plate

•

pH to 7.4-7.6

•

Pour into carboy

•	Bring volume to 5L
•	Store at 40C

KPBS +Sucrose 20% (100ml)
•

20g Sucrose

•

100ml KPBS

KPBS +0.3% Triton (1l)
•

997ml KPBS

•

3ul Triton X 100

•

Mix well

Na Acetate
•

1L MilliQ water

•

13.63 g Na Acetate

•

pH to 6.0 with 10% glacial acetic acid

•	Store at 40C

NAS (Nicke Ammonium Sulfate)
•

-500ml 5% NAS-

•

25g NAS

•

500ML 0.1M Sodium Acetate Buffer

•

pH 6.0

•	Store at 40C
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•
Normal Fixative- 4% PFA in Borate Buffer (pH 9.5)
•

1L MilliQ water

•	Heat and stir well until it reaches 60-650C
•

4g NaOH pellets/L (for 4L volume, use 16g)

•

40g PFA/L-> (for 4L use 160g)

•

38.14 Sodium Tetraborate (borax)/L (for 4L use 15205g)

•	Store at 40C, Filter if needed, pH to 9.5 with 10% glacial acetic acid

Normal Saline (0.85%)
•

8.5g NaCl

•

1L MilliQ water

•

Mix well and store at 40C

PBS
•

1L MilliQ water

•

0.256g Sodium Phosphate (monobasic)

o	Sodium phosphate (dibasic) anhydrate
•

8.75g NaCL

•

pH to 7.6

Thionin (for Nissl Stain)
•

1.44g NaOH

•

12ml glacial acetic acid

•

988mL MilliQ water

•	Heat mixture to near 600C
•	Heat to near 1000C
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•

While stirring, slowly add thionin (2.5g for a 0.25% solution)

•	Boil for 45 minutes (keep covered)
•	Filter and store in amber bottle
•	Filter before each use.

II.

Protein Work

Blocking Buffer (500ml)
•

500ml TBST (10X)

•

5g BSA OR 5g Powdered Milk (Great Value, Bentonville)

•

0.025g NaAzide

•

Mix well; store at room temp.

10 X Running (Laemmli) buffer (1L)
•

30.3g Tris Base

•

144.02g Clycine

•

900ml Milli Q water

•

10g SDS

•

Mix well, adjust volume to 1L. pH to 8.3

•	Store at room temp

1X Running (Laemmli) Buffer (1L)
•

100 ml 10X Running buffer

•

900ml Milli Q water

•

Mix well, store at room temp. Can be reused.

Stripping Buffer (1L)
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•

20g SDS

•

7.6g Tris base

•

1L MilliQ water

•

7.0 ml Beta-mercaptoethanol

•

Mix well, pH to 6.7

•

When ready to use, take 20 ml aliquot of buffer for stripping.

SDS PAGE Sample Buffer (10ml)
•

2.4 ml 1M Tris (pH 6.8)

•

0.8g SDS

•

4ml Glycerol

•

0.01% Bromophenol Blue (final – 0.02%)

•

2.8ml MilliQ water

•	Stir to dissolve; store at room temp in dark.
•	Add Beta-Mercaptoethanol before use (1ml) for reducing conditions

•

10X TBS

•

12.11g Tris Base

•

87.66g NaCl

•

1L MilliQwater

•

Mix well, store at room temp

10X TBST
•

12.11g Tris Base

•

87.66g NaCl

•

5ml tween-20

•

1g Na Azide
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•

1L MilliQ water

•

Mix well, pH to 7 .6; store at room temp.

10X Transfer buffer (1L)
•

900 ml Milli Q water

•

30.3g Tris Base

•

144.1g Glycine

•	Adjust volume to 1L
•	Store at room temp.
1X Transfer Buffer (1L)
•

100ml 10X transfer buffer

•

900ml MilliQ water

•

Mix well, store at room temp. Can be re-used.

88

VITA
After obtaining a B.S. in Biology and graduating summa cum laude from the University
of Texas at El Paso in the winter of 1999, I started graduate research with Dr. Todd Primm in
Mycobacterial spp. Stationary phase survival genetics, and moved toward proteomic research
using tandem mass spectrometry to analyze encystation proteins of the intestinal parasite Giardia
lamblia. Continually dismayed by the looks of disgust at parties when answering the, “So, what
do you do?” Question with, “I work with a diarrheal parasite,” I took a hiatus to explore life as a
freelance graphic artist, stained glass craftswoman, and Argentine tango dancer with my husband
and three cats.
In May of 2010, I wanted to finish what I had started back in 2000 and fell in love with
the world of neuroscience and neuroendocrine pathology. As a member of the VIDA project, an
interdisciplinary mentorship grant in topics of drug abuse, I was privileged to be able to escape
research myopia and enjoy being in a field that was immediately relevant, helpful and relatable.
My greatest joys in graduate school were my teaching opportunities. I love engaging with
students and finding out how best to explain new concepts and have a strong interest in building
up multi-modal curricula. As a neuroscientist I feel it is my job to study the brain so I can learn how
to teach the brain. The more pathways you engage and the more cues you lay on to the concepts
you present, the stronger the memory becomes!
Teaching and Mentoring Experience
•

SMART MINDS Graduate Mentor 2012, 2013, 2014

•

Assistant Instructor 2004-2005

•

Supplemental Instructor 1998

Research Experience
•

Graduate Researcher 2010-Present

•

Graduate Researcher 2003-2005

•

Research Assistant 2002-2003

Posters and Publications
89

•

Impact of homotypic stress exposure on methamphetamine self-administration in rats, 		

	C.E. D’Arcy, J.N. Hamdan, L.E. O’Dell, M. Miranda-Arango, K.L. Gosselink. Society 			
for Neuroscience 2014.
•	Repeated stress increases the rate of methamphetamine escalation in adult male rats, C. 		
	D’Arcy, J.N. Hamdan, L.E. O’Dell, K.L. Gosselink. Sun Conference 2014.
•	Associated differences in the effects of stress on reward-associated regions of the rat 		
brain. C.E. D’Arcy and K.L. Gosselink. Sun Conference 2012.
•	Neurological responses to repeated retraint stress are altered in hypertensive rats. C.E. 		
	D’Arcy and K.L. Gosselink. Society for Neuroscience 2011.
•

[Illustrations] D. Schulze-Makuch, L.N. Irwin (2004).Life in the Universe. New York, NW: 		

	Springer.

Christina Elizabeth D’Arcy
4324 Loma de Oro
El Paso, TX 79934
(915)821-2881

This dissertation was typed by Christina Elizabeth D’Arcy
90

